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ABSTRACT
Despite the advancement of antiretroviral therapy (ART), the development of
HIV associated neurocognitive disorders (HAND) remains a major concern among
HIV infected patients. As many ART drugs may fail to penetrate the blood-brain
barrier (BBB), the long-term presence of viral RNA in the brain is considered to
be associated with these disorders, such as early-onset dementia. In vivo study of
HIV infection in the brain is extremely difficult, and thus mathematical modeling
can help to further the analysis of the viral dynamics of HIV in the brain. In this
dissertation we develop a mathematical model to help investigate the viral dynamics
of HIV in the brain. Our model can explain containing viral loads in the plasma and
in the cerebral spinal fluid from SIV-infected macaques. We then extend this model
to study the treatment of HIV in the brain. Furthermore we develop a new stochastic
model to analyze any stochastic effects that may underlie HIV-viral dynamics in the
brain. Using our models, we show that the rate of transport of infected macrophages
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into the brain greatly exceeds the rate of transport out of the brain. We also show
that viral replication occurs in the brain, suggesting that the brain can act as a viral
reservoir. We also show that the basic reproduction number largely depends on the
overall effectiveness of ART, but it is not strongly affected by the rate of drug pene-
tration through the blood-brain barrier. The effectiveness of ART depends on both
pharmacodynamic parameters and a drug’s ability to penetrate through the BBB. In
particular, for drugs with a high dose-response curve, the BBB penetration strongly
affects the post-treatment control of the virus in the brain. Through examination of
the stochastic model we illustrate a prolonged higher likelihood of infection and viral
production in the brain compared to the plasma. Results in this dissertation may be
useful to develop HIV control strategies to target the virus hiding in the brain.
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CHAPTER 1
INTRODUCTION
Human immunodeficiency virus (HIV-1) is one of the most deadly diseases
in the world. According to the CDC [4] roughly 37 million people currently live in
the world with the disease, including 1.8 million new cases in 2017. In 2017, nearly
one million people died of HIV-1 globally. Restricting this to the United States the
numbers remain staggering, with roughly 1.1 million people in the United States
currently live with the disease, and nearly 40,000 new infections occurred in the year
2017.
Typically HIV-1 is transmitted between individuals via sexual intercourse or
via syringe and needle use. Transmission only occurs if contaminated blood (or fluids
such as breast milk, semen, pre-seminal fluid, rectal, and vaginal fluids) comes into
contact with damaged skin or is directly injected into the bloodstream. Once entered
into the system HIV-1 spreads rapidly throughout the body and eventually may lead
to Acquired Immunodeficiency Syndrome (AIDS) [4]. HIV-1 (Figure 1) in the form
of AIDS attacks and weakens the immune system and then may lead to opportunistic
infection of other diseases. Current treatment has progressed enough to allow infected
individuals to maintain an almost full lifespan with HIV-1, however no cure has yet
been found, despite potential recent success via stem-cell transplants [49]. Because
no cure exists, several studies explore methods to optimally control the virus.
A major barrier in the efforts to treat HIV-1 is the existence of viral reservoirs
1
Figure 1: Structure of an HIV virion [3].
in many sites such as the gut, liver, reproductive organs, and the brain [24, 27]. HIV
DNA resides latently within a reservoir, develops into virus particles and then leaks
into the plasma and reinfects the bloodstream. While each reservoir merits significant
research, the brain is the least studied reservoir. This is partly because in vivo study
is difficult and expensive, often requiring a spinal tap. As the lifespans of HIV-1
infected individuals has increased, the long-term virus within the brain often leads
to HIV-1 associated neurocognitive diseases (HAND) such as early-onset dementia
and encephalitis [18, 41, 43, 50, 51, 59]. It is thus critical to understand the viral
dynamics of HIV-1 in the brain.
HIV-1 enters the brain by crossing the blood-brain barrier (BBB) which facil-
itates transport of cells between the bloodstream and the brain [9, 12, 53]. Unfortu-
nately, antiretroviral drugs fail to pass through the BBB with the same effectiveness,
allowing the virus to persist in the brain despite ongoing treatment [46]. The virus
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then leaks out [13] again through the BBB back into the bloodstream and produces
more infection throughout the body. Hence, to study the viral dynamics of HIV-1 in
the brain it is paramount to consider the role of the BBB on viral transport.
Although some drugs may struggle to pass through the BBB, the treatment
of HIV-1 still plays a vital role in the control of HIV-1. Several types of drug mech-
anisms exist whose combinations make up what is called highly-active antiretroviral
therapy (HAART). The drugs target inhibiting some stage of the life-cycle of the
virus. Multiple studies [46, 48, 57, 63, 74, 75, 60] offer insight into the mechanisms of
these drugs and their overall effectiveness on HIV-1 control. A study by Letendre [46],
measured the permeability of commonly prescribed ART drugs through the BBB and
found that there are only a few drugs that show a stronger ability to pass through
the BBB. While these drugs often control the virus despite failing to eradicate it from
the system, they are crucial to the evaluation of HIV-1 in the brain.
Mathematical modeling has proven to be a useful tool to aid our understanding
of the viral dynamics of HIV-1 [14, 32, 34, 40, 56, 57]. However, limited studies have
been done which include the brain or the BBB. The goal of this dissertation is to
develop mathematical models that offer insights into the effects of the BBB on the
viral dynamics of HIV-1 in the brain, and on the effectiveness of treatment to control
the virus in the brain.
The dissertation is organized in as follows: In Chapter 2 we provide relevant
background for modeling HIV-1 dynamics as well as important biological information
about HIV-1, the BBB, and antiretroviral therapy. We also present various techniques
for theoretical analysis used in this dissertation.
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In Chapter 3 we develop a nonlinear ordinary differential equation (ODE)
model to study the role of the BBB on the viral dynamics of HIV-1 in the brain. The
model is parameterized using viral load data from macaques infected with a mixture
of simian-immunodeficiency virus (SIV) and simian-human-immunodeficiency virus
(SHIV). We conduct a thorough sensitivity analysis of the model parameters.
In Chapter 4 we develop and analyze an ODE model to examine the effect of
the BBB on the effectiveness of treatment to control HIV-1 in the brain. We also
conduct global stability analysis of the model. Furthermore, we examine the effect of
the drug pharmacodynamics, as well as the drug permeability through the BBB, on
the viral dynamics of HIV1.
In Chapter 5 we develop a stochastic differential equations (SDE) model to
study the impact of the stochastic nature of the virus-cell dynamical system. We com-
pare the simulations of the SDE model with the ODE model and analyze important
state probability distributions and likelihoods of infection events.
Finally, in Chapter 6 we discuss important findings of our study, biological
implications and future directions. We also present the conclusion of the dissertation.
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CHAPTER 2
BACKGROUND INFORMATION
In this chapter we provide a brief literature review of the biological aspects of
HIV as well as of relevant mathematical modeling for HIV viral dynamics. We also
detail some of the methods used in the theoretical analysis of the models developed
in this dissertation.
HIV Life Cycle
In order for HIV to spread, a free HIV virion must infect a cell. The most
common target cells are white blood cells known as helper T cells, specifically CD4+
T cells [2]. These cells play a major role in the immune system which fights against
infection within the body. Typically CD4+ T cells recognize foreign substances within
the body through coreceptors like CCR5 or CXCR4. A free HIV virion attaches to a
CD4+ T cell by binding to these coreceptors. After binding, the viral envelope fuses
with the cell and the viral RNA enters the CD4+ T cell and releases enzymes to begin
viral reproduction. The first enzyme, reverse transcriptase, allows the virus to convert
HIV RNA into HIV DNA, thus allowing HIV to enter the nucleus of the CD4+ T cell.
The second enzyme, integrase, allows the HIV DNA to insert itself into the DNA of
the T cell, and through the normal mitosis process of the T cell, viral HIV DNA is
then replicated. Since HIV is a retrovirus, these replications may not be exact. As
long chains of the HIV RNA are created by this process, they assemble outside of
the nucleus and move toward the surface of the cell. HIV is still non-infectious at
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this stage. The final stage, known as budding, occurs when the newly formed HIV
releases the enzyme protease to break up the long RNA protein chains of HIV into
smaller HIV RNA proteins, which bud off of the CD4+ T cell, and release into the
body [2]. A diagram of this process is provided in Figure 2.
Figure 2: The seven stages of the HIV life cycle [10]
An individual infected by HIV experiences two stages of infection before de-
veloping Acquired Immunodeficiency Syndrome (AIDS): acute infection and chronic
infection. During acute infection the viral load of HIV spikes, then dips to a con-
sistent (chronic) lower level that can maintain for several years. An individual may
express flu-like symptoms during acute infection.
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A CD4+ T cell is not the only target cell for HIV infection. Another cell,
known as a macrophage, is also commonly utilized for viral replication. This was first
discovered in 1986 by Koenig et al [41]. The infection process within macrophages
is similar to that of a CD4+ T cell, although the lifespan of a macrophage is much
longer than that of a CD4+ T cell [53]. Notably macrophages can enter into the brain
(the cerebral spinal fluid, or CSF), whereas a CD4+ T cell typically remains within
the plasma.
HIV Control and Treatment
In an effort to control the HIV replication process, HIV antiretroviral drugs
have been developed. These drugs are classified based on the part of the HIV life
cycle they disrupt. Specifically, the classes of HIV drugs are fusion inhibitors (FIs),
reverse transcriptase inhibitors (these are subclassified as non-nucleotide reverse tran-
scriptase inhibitors, NRTIs, and nucleotide reverse transcriptase inhibitors, NNRTIs,
respectively), integrase inhibitors (IIs), and protease inhibitors (PIs). The stage of the
HIV life-cycle that each class of drug inhibits is also marked in Figure 2. Treatment
plans including any combination of drugs were previously known as highly-active an-
tiretroviral therapy (HAART), although they are more commonly referred to simply
as antiretroviral therapy (ART).
ART treatments currently control HIV well enough such that an infected indi-
vidual currently undergoing ART may live to a normal lifespan. Long-term infection
of HIV has been shown to lead to nuerocognitive disorders like early-onset demen-
tia and encephalitis [42]. These chronic diseases are referred to as HIV-associated
neurocognitive disorders (HAND), and are currently an important area of study.
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Viral Reservoirs
After interruption of ART, HIV-infected individuals experience a rebound of
the virus. This is largely due to latent reservoirs of HIV [54]. A viral reservoir is
a site within the body which harbors viral RNA. Since the latently infected cells
do not produce virus at the current stage, ART fails to clear the virus from these
reservoirs, which allows for later activation after ART is withdrawn. Common HIV
viral reservoirs are the gut, liver, reproductive organs, and the brain [24, 31, 27].
The Brain and the BBB
Although CD4+ T cells rarely enter the brain, viral RNA copies have been
observed in the cerebral-spinal fluid (CSF) in as early as one week post-infection
[35, 51]. The CD4+ T cells fail to enter the brain due to the presence of the blood-
brain barrier (BBB). The BBB consists of a variety of endothelial cells, macrophages,
and astrocytes (see Figure 3), and mitigates transit of cells between the cerebral-
spinal fluid and the bloodstream by phosphorylation initiated by polarization [35].
Not only does the BBB prevent most CD4+ T cells from entering into the brain, but
also there is little evidence to suggest that free HIV-1 virions can pass through the
BBB. Instead, the virus infects immature macrophages (known as monocytes) which
take advantage of macrophage turnover within the BBB, and thus enter the brain.
This method is commonly referred to as the “Trojan-horse” method.
The BBB is a unique feature among the viral reservoirs of HIV, as productive
(rather than latent) free virions exist inside the CSF and reside even throughout
ongoing ART. It is not well understood how HIV acts within the brain, as in vivo study
is difficult. A study by Letendre et al. [46] provided a measure for the effectiveness of
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Figure 3: Schematic diagram of the blood-brain barrier [5]
ART drugs to permeate the BBB. Given the important role of the BBB on the virus
and drug entry, understanding the effect of the BBB on the viral dynamics of HIV
and ART is thus very important.
Viral Dynamics Modeling with a Deterministic Approach
In this section, we present a brief summary of articles that focus on within-host
HIV infection modeling, paying special attention to those related to viral reservoirs
and the brain. We also highlight a few experimental studies that are useful to devel-
oping models.
A deterministic viral dynamics model uses a system of ordinary differential
equations (ODE) that may or may not depend upon each other to represent incre-
mental rates of change. These rates are captured by model parameters and have been
widely useful in understanding natural phenomena.
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Some of the earliest deterministic models of HIV viral dynamics [40, 78] include
three compartments of cells: uninfected CD4+ T cells, T , infected CD4+ T cells, I ,
and free HIV virions, V (Figure 4).
Figure 4: The schematic diagram of the basic model of HIV-1 infection.
In this model the CD4+ T cells are generated at a constant rate λ , and die
at a per capita rate of d . Uninfected target cells become infected at a rate β when
they interact with free virions. These infected cells produce new virions at a rate of
p per infected cell. Infected cells die at a per capita rate δ . Free virions get cleared
at a constant per capita rate of c . Mathematically this model can be described by
the following system of ordinary differential equations (ODEs):
10
dT
dt
= λ− βV T − dT,
dI
dt
= βV T − δI,
dV
dt
= pI − cV.
(2.1)
This simple model showed remarkable success at describing the dynamics of
acute HIV infection [32, 57] and initiated the emergence of the field of study of viral
dynamics [55, 73].
Callaway and Perelson [14] extended the basic model (2.1) to consider two
infection compartments. This allowed them to study chronically infected cells, quies-
cent cells, latently infected cells, and even treatment. These models provided insight
into identifying populations of drug-resistant cells, and low steady-state viral loads.
In particular, from these models it was observed that target cells can respond differ-
ently to ART drugs. A major question from this study was whether drugs could be
developed to cross physiological barriers better, in the hopes of completely eradicating
HIV-1 from the human body.
Kim and Perelson [39] created a mathematical model of latent viral reservoirs.
This model describes the stability and decay characteristics of a latent reservoir. They
were able to model the “extremely slow decay” and stability of the latent reservoir due
to ongoing viral replication together with what they called bystander proliferation.
That is, nonstandard virus proliferation, for example, proliferation due to cytokines
in the environment. Their results suggest that even amid ongoing ART, low-level
viremia exists untreated within latent reservoirs. An excellent reference for further
review on mathematical models of latent HIV-1 infection can be found in Rong and
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Perelson [57].
The previous models were very effective in describing viral reservoirs, but
declined to specify the type of reservoir. The BBB’s unique mechanism for prevent-
ing treatment has had very little study by mathematical modeling. Recently Roda
et al. [56] developed a model to explore specifically the viral dynamics within the
brain. They used a simple model with only two compartments–uninfected and in-
fected macrophages. The results of the model suggest that the virus in the brain
can be eradicated depending on the comorbidity in the brain and the macrophage
lifespan.
Shortly after Roda et al. [56] published their study, another study by Huang et
al. [34] developed a model to analyze HIV persistence with regards to the lymphocyte
recirculation network within the CNS. The numerical results of their study illustrated
that plasma viral load data may not accurately reflect the overall viral mechanisms
of HIV within the human body. More research is clearly needed about HIV in the
brain.
Data Fitting
For a given system of Ordinary Differential Equations (ODEs), unknown pa-
rameters can be estimated by fitting a model solution to data. Throughout this
dissertation the ODEs presented are solved numerically using the MATLAB solvers
“ode15s” and “ode45”. For data fitting, the optimization functions “fmincon” and
“fminsearch” are used along with the common technique of the least squares method.
This method minimizes the sum of the squared residuals, that is, the difference be-
tween model predictions and their corresponding experimental data values. The for-
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mula below calculates the sum of the squared residuals.
J =
1
M
M∑
i=1
(y − yi)2 (2.2)
Here M represents the total number of data points considered for fitting and y and
yi represent the values predicted by the model and those from the experimental data,
respectively.
Once the best model parameters are computed from the least squares method,
it is common to further evaluate these parameters by finding confidence intervals
(CIs). CIs are calculated from n replications via bootstrapping the residuals from
the formula (2.2) [11, 23]. We note that this bootstrap method uses sampling with
replacement, so randomly selected data points may be repeated.
The process for generating CIs for estimated parameters by the bootstrapping
method is given as follows:
1) Select a sample of m data points;
2) Re-sample the m data points several times with replacement;
3) Perform a model simulation and calculate the residual error between the simulated
solution and the data point for each data point;
4) From the residual errors in the previous step compute their standard deviation,
σ ;
5) For each data point add a randomly chosen error term to each simulated solution
at that point and call it the new data point. The error is chosen from a normal
distribution with standard deviation σ .
6) Repeat the previous four steps n times;
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7) Run the model simulations using each of the n bootstrapped data points;
8) Calculate 95% confidence intervals based off the results of these simulations.
Model Comparison
A well-known method to compare the quality of mathematical models rela-
tive to each other is to use the Akaike Information Criterion (AIC). By comparing
computed AIC values, a model is chosen by taking the lowest AIC value calculated
among all models. The AIC is computed using the following formula [6]
AIC = P ln
(
J
P
)
+
2P (Np + 1)
P −Np − 2
, (2.3)
where J is the sum of the squared residuals from formula (2.2), P is the number of
data points used to fit the model, and Np is the number of parameters estimated for
the fitting. Note that ln(x) is meant as the logarithm of x with the natural base e .
The Basic Reproduction Number R0
For within-host models, a critical number that is highly analyzed is the basic
reproduction number, R0 . R0 represents the average number of secondary infections
arising from a single infected cell residing within entirely uninfected cells [22]. The
most common method to compute R0 is the next-generation operator method [22]. In
this method, we consider the equations related to infectious terms compartments and
linearize them about the infection-free equilibrium. Then we introduce two matrices,
the first matrix, denoted F , containing infection terms and the second matrix, V ,
containing the transfer terms. The total new infections can be thus represented by
the product, FV −1 . The basic reproduction number R0 is then taken to be the
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largest eigenvalue of FV −1 . In mathematical notation we consider the two matrices
F =
[
∂Fi(x0)
∂xj
]
, and V =
[
∂Vi(x0)
∂xj
]
, where Fi represents the new infections and Vi
represents the transfer terms. The value x0 represents the infection-free equilibrium
and the basic reproduction number, R0 , is the spectral radius given by ρ(FV
−1).
Equilibria, Bifurcation Analysis, and Stability
Mathematical models are most useful in their ability to model and predict
natural behavior and phenomena. Naturally, understanding the stability of system
solutions is necessary to validate the use of such a model. For a deterministic ODE
model an equilibrium solution is a model solution such that each derivative does not
change. This solution can be determined by setting all derivatives equal to zero. In
viral dynamics modeling, it is common to determine the infection-free equilibrium
(IFE). Moreover, equilibria may be stable or unstable depending on several features
of the system. While there are numerous methods to determine stability, one used in
this dissertation is the application of Lyapunov function. Utilizing Lyapunov’s second
method of stability [26] if one can find a Lyapunov function L : Rn → R , defined
to be a scalar function such that 1) L(x) = 0 if and only if x = 0, 2) L(x) > 0 if
and only if x 6= 0, and 3) dL(x)
dt
< 0 for all x 6= 0, then the equilibrium point x0 is
asymptotically stable, where x is the ODE system.
It may be the case that a single solution approaches an equilibrium point
under one set of conditions, yet under different conditions it may tend away from
an equilibrium point. The point in which the solution changes is commonly referred
to as a bifurcation point. Often in disease modeling the basic reproduction number
R0 helps determine such bifurcations. In particular, if the system parameters yield
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a solution that does not tend toward the infection-free equilibrium, by analyzing the
bifurcation it may be determined that viral infection persists.
Viral Dynamics Modeling with a Stochastic Approach
All modeling techniques so far have been deterministic by nature, but many
events including cell-to-cell interaction tends to occur with a degree of randomness
and uncertainty. Models using systems of stochastic differential equations (SDEs)
help capture this randomness by including a term of Brownian motion.
While many deterministic models have been developed to analyze HIV viral
dynamics, there have been far fewer stochastic models. An SDE population dynamic
model by Tuckwell et al. [72] used uninfected cells, infected cells, latently infected
cells, and viral particles to model early HIV infection. Another study by Tan et al.
[69] examined stochastic effects on HIV viral dynamics using Monte Carlo methods.
There are several methods to create SDE models [80, 7, 25], but in this disser-
tation we use a method developed by Cao and Gillespie [15]. This method is known
as the τ -leap method, which approximates a stochastic simulation algorithm (SSA)
by predicting common events and skipping over time differentials, or τ s. This differs
from the method proposed by Gillespie [25] in several ways, for example, the normal
random variables in the Gillespie SSA become Poisson random variables in the τ -leap
method.
A viral dynamics model using an SDE can be derived based upon the ODE
model from system (2.1). We now present an outline of the method. First we de-
termine the number of possible events that could occur in a small time interval and
represent each event with a vector of the state changes for each compartment. For
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example, if the states of each compartment are represented by ~X = [T, I, V ]tr , then
the vector ~X = [−1, 1,−1]tr represents the event that a single target cell becomes
infected. In this case of the basic [T, I, V ] model there are seven possible events,
including the event ~X = [0, 0, 0]tr , in which no change occurs. We then assign a
probability to each event determined by the model. For example, the uninfected T -
cell reaction ~X has a probability of p = dT . Note that the probability in this case is
identical to the rate from the deterministic model, although this is not generally the
case. The probability that no change occurs is simply the complement of the sum of
all events in which a state change takes place. The choice of which event occurs in a
given time interval depends on the probability of each event.
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CHAPTER 3
MODELING THE ROLE OF THE BBB ON THE HIV DYNAMICS IN THE
BRAIN
In this chapter we develop a novel mathematical model to describe the HIV-
1 viral dynamics in the brain. We identify key parameters by fitting our model
to plasma and CSF viral load data from an experiment using rhesus macaques in-
fected with a mixture of Simian Immunodeficiency Virus (SIV) and Simian-Human
Immunodeficiency Virus (SHIV). We consider three variants of the model to analyze
viral replication within the brain. We also explore the long-term stability of HIV-1
predicted by our model and determine its sensitivity to key parameters.
Introduction
The long-term effects of HIV-1 in the brain are devastating. Despite un-
detected viral load in the plasma during HAART, many patients experience HIV
associated neurocognitive disorders (HAND), such as encephalitis and early-onset de-
mentia [41, 46, 48, 63], mostly due to the extended period of infected individuals
carrying the virus supplied from the reservoirs. Among the viral reservoirs the brain
represents the least studied one [12, 13, 18, 24, 27, 46, 50], because of its unique
feature associated with the blood-brain barrier (BBB) and the difficulty of in vivo
study on the brain infection. It is important to get insights into the viral dynamics
in the brain to devise proper HIV-1 control strategies.
Recent studies have considered the virus in the brain as a major obstacle in
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the search for a cure [24, 31]. The brain has been recognized as a viral reservoir,
but it still remains unclear whether or not viral replication occurs within the brain
[27, 48, 57, 59, 63]. Some effort has been made to suppress the virus within the brain,
but the BBB drastically reduces the effectiveness of such treatment, partly because
many drugs cannot cross the BBB [9, 46]. Due to the difficulty in controlling HIV-1 in
the brain as well as potential viral replication inside it, the brain can be an important
reservoir causing an obstacle for a cure [12, 13, 34, 56]. There is a complex interplay
between the viral dynamics of HIV-1 within the brain and within the plasma and
mathematical modeling may be able to uncover new insight.
Materials and Methods
Data
The data used in this study was obtained by digitizing results from published
literature [44, 45]. In the published experiment [44, 45], three male rhesus macaques
(Macacamulatta) were infected intravenously with a mixture of simian-human im-
munodeficiency virus (SHIVKU−1B and SHIV89−6P ) and simian immunodeficiency
virus (SIV17E−Fr ). These animals were monitored for a period of 12 weeks, and lev-
els of circulating CD4+ T cells and viral loads in both the CSF and plasma were
measured as described in Kumar et al. [45].
Mathematical Model
In the circulation, one of the primary target cells of HIV-1 are uninfected
CD4+ T cells (T ). These cells become infected (T ∗ ) by free virions (V ) within the
circulation at a rate β . Infected CD4+ T cells die at a rate δ per day and produce
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virions at a rate of p per day per infected cell [74]. Uninfected T cells die at a rate
d and are generated at a rate λ .
The major cells that HIV-1 infects in the brain are macrophages [18, 32, 42]. To
model this we include an uninfected population of macrophages (M ) in the circulation
that becomes infected (M∗ ) upon interaction with free virus at a rate βM . These
infected macrophages produce free virions at a rate pM per day per infected cell and
die at a rate of δM per day. Uninfected macrophages die at a rate of dM and are
generated at a rate λM . Note that the population of macrophages has been considered
to contribute to viral persistence because of its longer lifespan [18, 24, 27, 31, 41, 43,
28, 57].
In order for a virion to enter the CSF in the brain it must pass through
the BBB. It is not fully understood what factors modulate transit of HIV-1 RNA
through the BBB into the CNS [31]. However studies show that the virus permeates
the integrity of the BBB only via an infected macrophage [9, 42]. We represent the
rate of the macrophage transit through the BBB by ϕ . Macrophages are not known
to generate independently within the brain [53]. The uninfected brain-macrophages
become infected (M∗B ) by the virus in the brain [12, 43, 50, 53, 59] at a constant
rate βM . These infected brain-macrophages produce free virions within the brain at
a constant rate pM per infected cell per day. The free virions in the brain have been
shown to possess different characteristics than those within the blood [46, 50, 53] and
we classify HIV-1 virions within the brain as VB . We assume that the free virions
V and VB are both cleared at the same per capita rate c . While limited evidence
suggests the possible presence of HIV-1-infected T cells within the CSF [68], because
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the primary targets of HIV-1 within the brain are macrophages [41, 42], we consider
only macrophages within the brain. Macrophages come out of the brain through the
BBB into the bloodstream at a constant rate ψ .
Considerable debate exists regarding whether or not viral replication occurs
within the brain [12, 24, 27, 31, 59]. To perform deeper analysis from the modeling
point of view, we develop three different variations of the model by introducing a
parameter α , which represents the fraction of infectivity (βM ) reduced in the brain
compared to outside of the brain. Model 1 (α = 0) assumes that viral replication
occurs within the brain at the same rate (βM ) as in the bloodstream. Similarly,
model 2 (α = 1) assumes that no viral replication occurs in the brain, and model 3
(0 < α < 1) assumes that the viral replication occurs at a lesser rate than outside of
the brain. Since the CSF viral load is significantly less than the plasma viral load,
we do not consider the case in which α > 1. The schematic diagram of the model is
shown in Fig 5. The model equations we use are as follows.
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dT
dt
= λ− βV T − dT,
dT ∗
dt
= βV T − δT ∗,
dM
dt
= λM + ψMB − βMVM − ϕM − dMM,
dM∗
dt
= βMVM + ψM
∗
B − ϕM∗ − δMM∗,
dMB
dt
= ϕM − ψMB − (1− α)βMVBMB − dMMB,
dM∗B
dt
= (1− α)βMVBMB − ψM∗B + ϕM∗ − δMM∗B,
dV
dt
= pT ∗ + pMM
∗ − cV,
dVB
dt
= pMM
∗
B − cVB.
(3.1)
Three variants of the model are Model 1: α = 0; Model 2: α = 1; Model 3:
0 < α < 1.
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Figure 5: The schematic diagram of the model representing HIV-1 infection
in the brain. The boxes represent a cell population, the solid arrows represent
transport from one population to another, and the dashed arrows represent the cause
for the corresponding events.
Parameter Estimation and Data Fitting
We take T0 = 38700 as in Vaidya et al. [73]. From Haney et al. [30] we
estimate M0 = 1463000 and MB0 = 20000. As estimated by Stafford et al. [67], the
average life span of uninfected target T cells is 100 days, which implies d = 0.01 per
day. Macrophages begin their life cycle as monocytes, and there are varying results
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regarding the age of the monocyte/macrophage lifespan ranging from three months
to three years [53]. We take the average lifespan to be approximately 18 months, i.e.
dM ∼ 0.002 per day. As every macaque was uninfected at the beginning of the study,
we take all infected cells to be zero, i.e., T ∗0 = M
∗
0 = M
∗
B0 = 0 [45]. Chen et al. [16]
estimated the SIV burst size in vivo in rhesus macaques as approximately 5 × 104
virions per infected cell, and the infected cell lives approximately one day, thus we
take p = 50, 000. Assuming a steady state before infection, we use λ = dT0 and
λM = dM(M0 +MB0) to estimate λ and λM . Schwartz et al. [73] estimated the rate
of lentiviral production by an infected macrophage to be approximately 1000 virions
per infected cell per day. Therefore, we set pM = 1000 for our base case computation.
The virion clearance rate during chronic infection in humans varies from 9.1 to 36.0
[54]. Thus we take the average c = 23 per day as the minimal estimate. However, we
acknowledge that this rate may be higher in macaques.
We estimate the remaining parameters β, βM , δ, δM , ϕ, ψ by fitting the model
to the viral load data in the CSF and the plasma. We solve the system of ordinary
differential equations (ODEs) numerically using the “ode15s” solver in MATLAB.
The predicted log10 values were fitted to corresponding log-transformed viral load
data using the nonlinear least square regression, in which the sum of the square
residuals, that is, the difference between the model predictions and the corresponding
experimental data, is minimized. We used the following formula to calculate the sum
of the squared residuals:
J =
1
P
P∑
i=1
(
log10 V (ti)− log10 V̄ (ti)
)2
+
1
N
N∑
i=1
(
log10 VB(ti)− log10 V̄B(ti)
)2
, (3.2)
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where P and N represent the total number of data points in the plasma and in
the brain, respectively. V and V̄ , represent the virus concentrations in the plasma
predicted by the model and those measured in the experimental data, respectively,
while VB and V̄B represent the virus concentrations in CSF predicted by the model
and those measured in the experimental data, respectively. For each best fit parameter
estimate, we provide 95% confidence intervals (CI), which were computed from 500
replicates by bootstrapping the residuals [11, 23].
Results
Model Selection
We fit the model to the data containing plasma viral load and the CSF viral
load for each of the three monkeys. To compare models we used the Akaike informa-
tion criterion (AIC) described by the following formula [6].
AIC = n log
(
J
n
)
+
2n(Np + 1)
n−Np − 2
, (3.3)
where n = P + N represents the total number of data points considered, J is the
sum of the squared residuals (SSR), and Np represents the number of parameters
estimated through data-fitting. The SSR and the AIC values for each of the model
1, model 2, and model 3 are given in Table 1. Note that the lower the AIC value, the
better the model fit.
There is no significant difference in the AIC or SSR value between Model 1
and Model 2, but Model 3 has the highest AIC values (Table 1). This indicates that
Model 3 does not explain the data well compared to the other models. While we
acknowledge that the AIC values do not significantly differ between Model 1 and
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Table 1: SSR and AIC values for each of the model 1 (α = 0), model 2 (α = 1), and
the model 3 (0 < α < 1) fitted to each of the three monkeys.
Model 1 (α = 0) Model 2 (α = 1) Model 3 (0 < α < 1)
SSR AIC SSR AIC SSR AIC
Monkey 1 4.6235 17.1562 4.4903 16.7469 3.8943 26.8866
Monkey 2 2.4144 55.788 2.4163 55.7966 2.4159 145.7951
Monkey 3 4.9797 18.1952 4.9758 18.1841 4.9781 30.3239
Model 2, Model 1 is supported by the previous study by Schnell [59], in which the
rate of infectivity for macrophages in the brain is the same as that outside the brain.
Therefore, we select the model 1 to present the subsequent results in the sections to
follow.
The prediction of the selected model, i.e. Model 1, along with the data for
each of the three monkeys are shown in Fig. 6. Our model agrees well with the data
(Fig. 2). The estimated parameters are given in Table 2.
Rates of Infection and Cell Death
We estimated that the rate, β , at which the virus infects CD4+ T cells,
ranges between 2.58×10−8 and 4.40×10−8 viral RNA copies per ml per day. These
estimates are consistent with the previous estimates [74]. The infection rate estimated
for macrophages, βM , ranges between 4.01×10−11 and 1.00× 10−9 viral RNA copies
per ml per day, implying that macrophages are less susceptible to viral infection
than CD4+ T cells. Similarly, we found that the death rate of infected macrophage
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Figure 6: Model fit to the data. Plasma viral load (solid line) and CSF viral
load (dashed line) predicted by the selected model, i.e. Model 1, along with the
experimental data (filled circle: plasma viral load; filled triangle: CSF viral load)
from three monkeys [44, 45].
(median δM ∼ 0.21 per day) is significantly lower than the death rate of infected
CD4+ T cells (median δ ∼ 1.61 per day). Thus our model suggests that infected
macrophages persist with the virus far longer than infected T cells, which is consistent
with findings from previous experiments [43, 51, 53].
Reproduction Number
The basic reproduction number (R0 ) is defined as the average number of
secondary infected cells produced by a single infected cell when there is no target cell
limitation [76]. In viral dynamics, the basic reproduction number is an important
threshold that can determine whether infection occurs. Specifically, if R0 < 1 the
infection dies out, and if R0 > 1 the infection occurs [76]. For our model we use the
next-generation method [22, 76] to compute R0 .
Our model possesses a unique infection-free equilibrium (IFE), given by
(T∗, 0,M∗, 0,MB∗, 0, 0, 0),
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where
T∗ =
λ
d
,
M∗ =
λM(ψ + dM)
(ϕ+ dM)(ψ + dM)− ψϕ
, and
MB∗ =
λMϕ
(ϕ+ dM)(ψ + dM)− ψϕ
.
Following the next generation matrix method, we linearize the five model equations
corresponding to infection classes, i.e. , T ∗ , M∗ , M∗B , V , and VB , about the IFE and
introduce the following matrices:
F =

0 0 0 βλ
d
0
0 0 0 βMλM (ψ+dM )
(ϕ+dM )(ψ+dM )−ψϕ
0
0 0 0 0 βMλMϕ
(ϕ+dM )(ψ+dM )−ψϕ
p pM 0 0 0
0 0 pM 0 0

,
and
V =

δ 0 0 0 0
0 ϕ+ δM −ψ 0 0
0 −ϕ ψ + δM 0 0
0 0 0 c 0
0 0 0 0 c

,
where F represents a matrix of new infections and/or viral production in the lin-
earized system and V represents a matrix of the transfer of cell or virus into and out
of the compartment. The basic reproduction number is then given by the spectral
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radius of FV −1 . That is,
R0 =
1
2ϕψAD
·
[
√
2
√
ϕψAD
(
AB + CE +
√
(AB)2 +HC2 + C(B + C)G+BCΨ
)]
,
where
A =
ϕ2 + δMϕ+ dMϕ+ 2ϕψ + ψ
2 + δMψ + dMψ + dMδM
ϕψ
, B = pβλδMdMϕψ,
C = pMβMλMδdϕψ, D = dMcδdδM , E = ϕ
2 + 2δMϕ+ ϕψ + dMψ + dMδM ,
G =
ϕ4 + (ϕψ)2 + 2dMψ(ϕ
2 + δMϕ+ dMδM)
(ϕψ)2
, H =
1 + ψ2 − 2dMδMϕ2 + 2dMϕψ2
(ϕψ)2
,
and
Ψ =
1
(ϕψ)2
(
−3ϕ4 − 2ϕ2ψ + (dM + δM)(−2ϕ3 + 2dMψ(ψ + δM))
+2(ϕ+ dM)(ψ
3 + dMδM) + (ϕψ)
2 + 2dMδM(ψ
2 + dMδM)
)
.
We now use the parameters estimated above to obtain the basic reproduction number
for each monkey. We found that R0 ranges from 1.33 to 1.55. Note that R0 > 1 in
each case as expected because the experimental data show that the infection persists
in each monkey. We further perform the sensitivity analysis to identify how sensitive
the value of R0 is to each parameter. To quantify the sensitivity we considered the
sensitivity index Sx [58], given by
Sx =
(
X
R0
)(
∂R0
∂X
)
,
where X is a parameter whose sensitivity is sought. Based on the Sx values (Fig.
7), we identified that the parameters d, β, p, c, δ , and λ have the greatest influence
on R0 , whereas ϕ, ψ, dM , βM , pM , δM , λM have much less effect. We observe that the
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Figure 7: Sensitivity of Parameter Estimations to R0
parameters greatly influencing R0 are mostly T cell related. Thus the T cell and
related parameters are primary contributors to the initial establishment of the viral
infection.
Transport Through the BBB
Regarding infection in the brain, the transport of virus through BBB plays a
critical role. These mechanisms can be studied through the parameters ϕ and ψ of
our model. Our estimates show that the per capita rate of macrophage entry into the
brain, ϕ ∼ 0.29 per day, is significantly less than the per capita rate of macrophage
exit from the brain, ψ ∼ 9.41 per day (Table 2). This implies that the transport
of virus out of the brain via infected macrophages can be greater than the transport
of virus into the brain. As a result, the amount of virus, which replicates inside the
brain and then exits into the bloodstream through the BBB, can be significantly high.
Thus the brain may act as an HIV-1 reservoir supplying HIV-1 into the bloodstream
causing the persistent infection despite control of virus in the bloodstream through
successful treatment.
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Because of potential selection imposed by the BBB, especially for the entry
of virus into the brain, we ask a question whether inflow of virus into the brain is
constant and thus the brain compartment can be studied in isolation as done in some
previous study [56]. To analyze viral entry into the brain we calculated the rate of
number of infected macrophages (ϕM∗ ) entered into the brain over time for 100 days
post-infection (Fig. 8). The model prediction suggests that infected macrophages
enter the brain through the BBB at time-varying rate, depending upon the infection
outside the brain. This indicates that the brain and the plasma must be considered
as one coupled system rather than two separate ones to accurately predict the viral
dynamics in the brain, at least during the acute phase of infection.
Figure 8: Incoming infected macrophages entering the brain (ϕM∗). Model
simulations of the total count of infected macrophages (ϕM∗ ) entering the brain for
100 days post-infection.
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Cell and Virus Dynamics
We first used our model to study the acute phase dynamics of macrophages
(Fig. 9). The infected macrophages in the plasma and the brain both reach a peak at
approximately 18 days post-infection, and then decline steadily over the next three
weeks, eventually reaching a set point level. The dynamics of infected macrophages
in the brain is similar to that of the infected macrophages in the plasma, however the
amount of infected macrophages in the brain is significantly lower (peak at ≈ 170
per µL) than the infected macrophages in the plasma (peak at ≈ 40, 000 per µL).
This small amount of infected macrophages hiding inside the brain may explain the
low level of viral persistence during the treatment of infected patients as many drugs
cannot enter the brain through the BBB [46]. The uninfected macrophages, both in
the brain and in the plasma, decline rapidly (by ≈ 6%) of their initial amounts.
We also studied a long-term dynamics by performing model simulations for
1000 days (approximately 3 years). After approximately 200 days the CD4+ T cell
count, the infected macrophages in the brain and the plasma, and the viral RNA
copies in the brain and the plasma all reach a steady state (Fig 10). The steady state
level of the infected macrophages in the brain is roughly one fourth of that outside the
brain (200 per µL outside vs 50 per µL inside the brain). Similarly, the steady-state
level of viral RNA in the brain is nearly threefold less than that in the plasma (≈ 103
vRNA copies in the brain vs. ≈ 106 vRNA copies in the plasma), consistent with
the experimental results [45]. The CD4+ count drops rapidly and levels off at 400
shortly after day 200.
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Figure 9: Simulations of macrophages in the plasma and the CSF. Model
simulations over 100 days post-infection of infected macrophages (top row) and unin-
fected macrophages (bottom row) in the plasma (left column) and in the brain (right
column).
Sensitivity Analysis
Sensitivity of data-fitting estimates on the fixed parameters. Our
data-fitting estimates were based on the fixed values of parameters M0 , MB0 , dM ,
and pM . While we estimated values of these parameters from the literature, there is
uncertainty with these values. Therefore, we performed the sensitivity of the data-
fitting parameter estimates to the choice of the initial conditions M0 and MB0 (Fig.
11) and the choice of dM and pM (Fig. 12).
First, we performed 200 different data fittings using M0 and MB0 values cho-
sen randomly from the uniform distribution between 10% less and 10% more values
than the base value. We observed that the median change in the estimated parame-
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Figure 10: Long-term model simulations. Viral load (top left) for the plasma
(solid line) and the brain (dashed line) along with the CD4+ T cell count (top right)
and the total infected macrophages (bottom row) in the brain (bottom left) and in
the plasma (bottom right).
ters remained below 10% for each parameter and for each monkey except for βM in
Monkey 2 (22% change) (Fig. 11). This high sensitivity of βM for Monkey 2 is likely
due to the lack of enough data points in the brain for this monkey. The overall mean
change of each estimated parameter also remained less than 10% from the base case
estimate, suggesting our estimates were robust within these ranges of M0 and MB0 .
Then, we also performed 200 data fittings using dM and pM values sampled
randomly from the values between 10% less and 10% more than the base values. In
this case, we observed that both the median and the mean change in the estimated
parameters never exceeded more than 8% for each parameter for each monkey. This
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suggests that our parameter estimates for dM and pM were also robust within these
ranges for dM and pM .
Sensitivity of model dynamics on the general parameter space. Given
the limited number of data sets and extreme complications for the study of brain
virus, the results based on the model dynamics from our limited estimates require
further analysis on a wider parameter space. To examine the robustness of our model
dynamics we performed 200 simulations using a Latin hypercube sampling (LHS) of
nine parameters (δM , ψ , ϕ , βM , β , MB0 , M0 , pM , and dM ). The box-plots and
partial rank correlation coefficients of this sensitivity analysis is shown in Fig. 13 and
14, respectively. The dynamics from the data fitting estimates (solid lines) are clearly
captured within the boxes of the LHS results. Predicted dynamics are more sensitive
to the parameters during early part of the infection. Variation of the viral dynamics
in the brain is much wider than that in the plasma (Fig. 13).
We calculated PRCC values at weeks one, two, three, and 26, corresponding to
the timings for pre-peak, peak, post-peak, and set point viral load, respectively (Fig.
14). The computed partial rank correlation coefficients indicate that, parameters, in
general, have stronger correlation to the viral load in the CSF compared to that in
the plasma. Both plasma and CSF viral load are most correlated with parameters
related to infection rates, βM and β , and macrophage life-span, δM . In addition,
the CSF viral load is highly correlated with the BBB related parameter, ϕ . These
parameters, except δM , mainly have larger effect on early viral load than in the late
viral load. Both plasma and CSF viral loads are positively impacted by βM and β ,
and negatively impacted by δM , while ϕ has positive impact on CSF viral load and
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Table 2: Parameter estimates through data fitting. Estimated parameters from
fitting the selected model, i.e. Model 1, to each of the three monkey’s data. Paired
values in parentheses represent 95% confidence intervals.
δ δM ϕ ψ β βM
day−1 day−1 day−1 day−1 ml/day ml/day
Monkey 1
1.7319
(0.5555,1.8049)
0.2067
(0.1405,0.4141)
0.0117
(0.00220,0.22342)
9.4052
(8.2458,10.8779)
3.7332E-8
(1.9456E-8,7.4280E-8)
1.0018E-9
(9.9297E-10,1.0000E-9)
Monkey 2
1.6129
(0.8940,1.8214)
0.0673
(0.0234,0.1256)
0.78565
(0.33675,2.3305)
15.0023
(14.4669,15.2483)
4.4009E-8
(3.5322E-8,7.3811E-8)
4.0068E-11
(1.0000E-11,4.0119-11)
Monkey 3
1.0766
(0.5941,1.1664)
0.2127
(0.1550,0.2797)
0.29149
(0.08801,0.91395)
8.8010
(8.6176,9.0556)
2.5809E-8
(1.8701E-8,2.6271E-8)
6.9003E-10
(3.5739E-10,9.3840E-10)
Figure 11: Box-plots of the parameter estimates from 200 data-fittings with
values of M0 and MB0 selected randomly from ±10% of the base values.
Each subfigure represents the result for one of the parameters estimated.
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Figure 12: Box-plots of the parameter estimates from 200 data-fittings with
values of dM and pM selected randomly from ±10% of the base values.
Each subfigure represents the result for one of the parameters estimated.
negative impact (but with smaller magnitude) on the plasma viral load.
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Figure 13: Box-plots of the results of 200 simulations of the Model from
Latin hypercube sampling. The sensitivity of the dynamics of plasma viral load
(top) and the CSF viral load (bottom) based on 200 Latin Hypercube sampling. The
black sold line represents the viral dynamics predicted by the model with median
parameters estimated from three monkey data.
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Figure 14: Partial rank correlation coefficients from the Latin hypercube
sampling method. PRCC values of the plasma (top) and the CSF (bottom) viral
loads at weeks 1 (pre-peak), 2 (peak), 3 (post-peak), and 26 (set-point) post infection.
39
CHAPTER 4
EFFECTS OF THE BLOOD-BRAIN BARRIER ON THE TREATMENT OF
HIV-INFECTION IN THE BRAIN
In this chapter we develop a mathematical model to analyze the effect of the
BBB on the overall treatment of HIV in the brain. We consider ART by varying
key drug parameters such as the CPE score, the slope of the dose-response curve,
and the initial treatment date. We also analyze the model to establish the local and
global properties of the infection dynamics. We show how varying the slope of the
dose-response curve, the CPE score, and the time of treatment initiation affects the
viral loads in the plasma and in the brain, and the time that viral loads become
undetectable.
Introduction
In Chapter 3, we developed a model that adequately described the viral dy-
namics of HIV-1 in the brain. We obtained interesting results that suggested new
parameters to measure the transport of macrophages through the BBB. These results
provided the need to examine the effect of the BBB on the treatment of HIV-1. Cur-
rent ART drugs fail to fully penetrate through the BBB, resulting in reduced efficacy
in the brain. Thus it is important to study what effects this reduced drug efficacy in
the brain may impose on the overall treatment of HIV-1.
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Model
Model Development
We develop a model with treatment by incorporating treatment terms into the
model previously developed in Chapter 3. We describe the viral dynamics using the
following differential equations, and a schematic diagram of the model is presented in
Figure 15. All parameter values are given in Table 3.
dT
dt
= λ−
n∏
i=1
(1− εi)βV T − dT,
dT ∗
dt
=
n∏
i=1
(1− εi)βV T − δT ∗,
dM
dt
= λM −
n∏
i=1
(1− εi)βMVM − ϕM + ψMB − dMM,
dM∗
dt
=
n∏
i=1
(1− εi)βMVM + ψM∗B − ϕM∗ − δMM∗,
dMB
dt
= ϕM − ψMB −
n∏
i=1
(1− επi)βMVBMB − dMMB,
dM∗B
dt
=
n∏
i=1
(1− επi)βMVBMB − ψM∗B + ϕM∗ − δMM∗B,
dV
dt
=
∏
i=1
(1− εPIi) pT ∗ +
∏
i=1
(1− εPIi) pMM∗ − cV,
dVB
dt
=
∏
i=1
(1− επPIi) pMM∗B − cVB.
(4.1)
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Figure 15: Schematics for model with treatment
Currently there are five available classes of ART drugs: Fusion Inhibitors
(FIs), Nucleoside reverse transcriptase inhibitors (NRTIs), Non-nucleoside reverse
transcriptase inhibitors (NNRTIs), Integrase inhibitors (IIs), and Protease inhibitors
(PIs) [4]. The efficacy of each drug, ε , can be calculated by the formula [75]:
ε = 1−
 1
1 +
(
D
ED50
)m
 ,
where m is Hill’s coefficient, D is the amount of drug concentration present, and
ED50 represents the concentration of drugs required to obtain 50% of the maximal
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effect. Note that Hill’s coefficient is also considered to be the slope of the dose-
response curve of a given drug. ART drugs reduce the respective viral production
rates p , and pM to (1 − εPIi)p and (1 − εPIi)pM , in the case of PIs, or reduce the
infection rates β , and βM to (1 − εi)β and (1 − εi)βM , respectively, for other drug
classes. When multiple drugs are used in treatment, the net reduction is given by the
product of drug effectiveness values, that is, for FIs, IIs, and RTIs, the infection rates
are reduced to
n∏
i=1
(1− εi)β and
n∏
i=1
(1− εi)βM , and for PIs the viral production rates
are reduced to
n∏
i=1
(1− εPIi)p and
n∏
i=1
(1− εPIi)pM .
The BBB reduces the net effectiveness of ART drugs by limiting the amount
of concentration into the CSF. A study by Letendre et al. [46] examined the viral
loads in the CSF in the presence of ART drugs and created a standard measure (CNS
penetration effectiveness score, or CPE-score) for the effectiveness of an ART drug at
entering the brain. Based on this study, we construct the parameter, π , to represent
this dampening effect as follows:
π =
CPE Score
5
,
where the CPE score (or CNS penetration effectiveness score) ranges from zero to
five. In particular, for drugs crossing the BBB we have
επ = 1−
 1
1 +
(
πD
ED50
)m
 .
Here a lower CPE score implies a lower concentration of the ART drug in the CSF.
For our purposes we consider a score of five to means that a drug maintains an equal
effectiveness in the brain as it does in the plasma. Similarly, a minimum score of zero
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implies that the drug cannot penetrate through the BBB.
Model Analysis
For ease of notation we now define the following variables:
Φb =
n∏
i=1
(1− εi) , Φp =
n∏
i=1
(1− εPIi), and
Φπb =
n∏
i=1
(1− επi), Φπp =
n∏
i=1
(1− επPIi).
Model Feasibility
In view of [65, Theorem 5.2.1], it follows that for any
(T0, T
∗
0 ,M0,M
∗
0 ,MB0,M
∗
B0, V0, VB0) ∈ R8+,
system (4.1) has a unique local nonnegative solution
(T (t), T ∗(t),M(t),M∗(t),MB(t),M
∗
B(t), V (t), VB(t)) ∈ R8+
through the initial value:
(T (0), T ∗(0),M(0),M∗(0),MB(0),M
∗
B(0), V (0), VB(0))
= (T0, T
∗
0 ,M0,M
∗
0 ,MB0,M
∗
B0, V0, VB0).
Substituting
N(t) = T (t) + T ∗(t) +M(t) +M∗(t) +MB(t) +M
∗
B(t) (4.2)
into system (4.1), leading to the following inequality
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dN
dt
= λ− (dT + δT ∗) + λM − dM(M +MB)− δM(M∗ +M∗B)
≤ λ+ λM − dmin(T + T ∗ +M +M∗ +MB +M∗B)
= λ+ λM − dminN,
where dmin := min{d, δ, dM , δM} , and hence,
lim
t→∞
N(t) ≤ λ+ λM
dmin
. (4.3)
This implies that N(t) is ultimately bounded, so are T (t), T ∗(t), M(t), M∗(t),
MB(t) and M
∗
B(t), due to (4.2) and the positivity of solutions. Then there exist
t0 > 0 and Λ > 0 such that
ΦppT
∗(t) + ΦppMM
∗(t) ≤ Λ and ΦπppMM∗B(t) ≤ Λ, ∀ t ≥ t0.
From the seventh and eighth equations of (4.1), we see that
dV
dt
≤ Λ− cV, ∀ t ≥ t0,
and
dVB
dt
≤ Λ− cVB, ∀ t ≥ t0.
Thus,
lim
t→∞
V (t) ≤ Λ
c
, and lim
t→∞
VB(t) ≤
Λ
c
,
that is, we have shown that V (t) and VB(t) are ultimately bounded.
From the above discussion and Theorem 3.4.8 in [29], we have the following
result:
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Theorem 1. R8+ is positively invariant for system (4.1) and system (4.1) admits
a unique and bounded solution with the initial value in R8+ . Further, system (4.1)
admits a connected global attractor on R8+ which attracts all positive orbits in R8+ .
Basic Reproduction Number
We first determine the infection-free equilibrium, E0 , of system (4.1). To this
end, we substitute T ∗ = M∗ = M∗B = 0 into system (4.1), and we have V = VB = 0.
Furthermore, we arrive at the following systems:
dT
dt
= λ− dT, (4.4)
and 
dM
dt
= λM − (ϕ+ dM)M + ψMB,
dMB
dt
= ϕM − (ψ + dM)MB.
(4.5)
It is easy to see that system (4.4) admits a unique positive equilibrium T̂ := λ
d
, which
is globally attractive in R+ . We also see that
(M̂, M̂B) =
(
λMa
dM
,
λM(1− a)
dM
)
(4.6)
is the unique positive equilibrium of system (4.5), where a = ψ+dM
ϕ+ψ+dM
. Since sys-
tem (4.5) is cooperative (see, e.g., [65]) and it admits a unique positive equilibrium
(M̂, M̂B), we can show the global stability of (M̂, M̂B) (see, e.g., [36]). The following
results are concerned with the dynamics of systems (4.4) and (4.5).
Lemma 1. The following statements are valid.
(i) System (4.4) admits a unique positive equilibrium T̂ := λ
d
, which is globally
attractive in R+ .;
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(ii) System (4.5) admits a unique positive equilibrium (M̂, M̂B) which is globally
attractive in R2+ , that is, for any (M(0),MB(0)) ∈ R2+ , we have
lim
t→∞
(M(t),MB(t)) = (M̂, M̂B).
From the above discussions, the infection-free equilibrium of system (4.1) takes
the form
E0 = (T, T
∗,M,M∗,MB,M
∗
B, V, VB) = (T̂ , 0, M̂ , 0, M̂B, 0, 0, 0).
The equations for the infected cells and free virions in the plasma and the brain of
the linearized system at the infection-free equilibrium, E0 , take the form
dT ∗
dt
= ΦbβT̂V − δT ∗,
dM∗
dt
= ΦbβMM̂V + ψM
∗
B − (ϕ+ δM)M∗,
dM∗B
dt
= ΦπbβMM̂BVB + ϕM
∗ − (ψ + δM)M∗B,
dV
dt
= ΦppT
∗ + ΦppMM
∗ − cV,
dVB
dt
= ΦπppMM
∗
B − cVB.
(4.7)
The spectral bound or the stability modulus of an n×n matrix M , denoted by s(M),
is defined by
s(M) := max{Re(λ) : λ is an eigenvalue of M}.
Motivated by (4.7), we define the following matrix:
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J =

−δ 0 0 ΦbβT̂ 0
0 −(ϕ+ δM) ψ ΦbβMM̂ 0
0 ϕ −(ψ + δM) 0 ΦπbβMM̂B
Φpp ΦppM 0 −c 0
0 0 ΦπppM 0 −c

. (4.8)
Clearly, J has non-negative off-diagonal elements, and J is irreducible (see a simple
test on page 256 of [66]). Then s(J) is a simple eigenvalue of J with a positive
eigenvector (see, e.g., [66, Theorem A.5]).
We now use the next generation matrix method [76] to compute the basic
reproduction number, R0 . We introduce the following matrices:
F =

0 0 0 ΦbβT̂ 0
0 0 0 ΦbβMM̂ 0
0 0 0 0 ΦπbβMM̂B
Φpp ΦppM 0 0 0
0 0 ΦπppM 0 0

, (4.9)
and
V =

δ 0 0 0 0
0 ϕ+ δM −ψ 0 0
0 −ϕ ψ + δM 0 0
0 0 0 c 0
0 0 0 0 c

. (4.10)
Note that J = F − V . The basic reproductive number corresponds to the spectral
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radius of FV −1 ,
R0 = ρ(FV
−1).
The following is a general result showing that the local stability of the disease-free
equilibrium, E0 , is determined by R0 (see, e.g. [76, Theorem 2]):
Lemma 2. The following statements hold.
(i) R0 = 1 if and only if s(J) = 0;
(ii) R0 > 1 if and only if s(J) > 0;
(iii) R0 < 1 if and only if s(J) < 0.
Thus, the disease-free equilibrium E0 is locally asymptotically stable if R0 < 1, and
unstable if R0 > 1.
Clearly the reproduction number is a function of the treatment effectiveness
parameters, εi and εPIi . In Figure 16 we show the change in R0 based on these
parameters as well as the total region in which R0 ≥ 1 depending on the drug
efficacies of ART drugs.
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Figure 16: Graph of the reproduction number R0 (left) and the region in which
R0 > 1 (right). We plot R0 (z -axis) compared to the effectiveness of PIs (x-axis)
and RIIs (y -axis). The horizontal plane represents when R0 = 1.
Threshold Dynamics
This subsection is devoted to the study of the threshold dynamics of system
(4.1). Let
X0 = {(T0, T ∗0 ,M0,M∗0 ,MB0,M∗B0, V0, VB0) ∈ R8+ : T ∗0 > 0, M∗0 > 0, M∗B0 > 0,
V0 > 0, VB0 > 0},
and
∂X0 := R8+\X0 = {(T0, T ∗0 ,M0,M∗0 ,MB0,M∗B0, V0, VB0) ∈ R8+ :
T ∗0 = 0 or M
∗
0 = 0 or M
∗
B0 = 0 or V0 = 0 or VB0 = 0}.
Lemma 3. Assume that
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(T (t), T ∗(t),M(t),M∗(t),MB(t),M
∗
B(t), V (t), VB(t))
is a solution of the system (4.1) with initial value
(T (0), T ∗(0),M(0),M∗(0),MB(0),M
∗
B(0), V (0), VB(0)) ∈ X0.
Then
(T (t), T ∗(t),M(t),M∗(t),MB(t),M
∗
B(t), V (t), VB(t)) 0, ∀ t > 0.
PROOF. In view of the first equation of system (4.1), it follows that
T (t) = e−
∫ t
0 b1(s1)ds1
[∫ t
0
λe
∫ s2
0 b1(s1)ds1ds2 + T (0)
]
,
where
b1(t) := d+ ΦbβV (t).
Thus, T (t) > 0, ∀ t > 0. From the third equation of system (4.1), it follows that
M(t) = e−
∫ t
0 b2(s1)ds1
[∫ t
0
e
∫ s2
0 b2(s1)ds1a2(s2)ds2 +M(0)
]
,
where
a2(t) := λM + ψMB(t) ≥ λM ,
and
b2(t) := ΦbβMV (t) + ϕ+ dM .
Thus, M(t) > 0, ∀ t > 0. From the fifth equation of system (4.1), it follows that
MB(t) = e
−
∫ t
0 b3(s1)ds1
[∫ t
0
e
∫ s2
0 b3(s1)ds1a3(s2)ds2 +MB(0)
]
,
where
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a3(t) := ϕM(t) > 0,
and
b3(t) := ψ + ΦπbβMVB(t) + dM ≥ ψ + dM .
Thus, M(t) > 0, ∀ t > 0. Next, we regard Theorem 4.1.1 of [65] as a generalized
version to nonautonomous systems, and the irreducibility of the cooperative matrix
−δ 0 0 ΦbβT (t) 0
0 −(ϕ+ δM) ψ ΦbβMM(t) 0
0 ϕ −(ψ + δM) 0 ΦπbβMMB(t)
Φpp ΦppM 0 −c 0
0 0 ΦπppM 0 −c

(4.11)
implies that
(T ∗(t),M∗(t),M∗B(t), V (t), VB(t)) 0, ∀ t > 0.
This completes the proof. tu
Theorem 2. The following statements hold.
(i) If R0 < 1, then the disease-free equilibrium E0 is globally attractive in R8+
for (4.1);
(ii) If R0 > 1, then system (4.1) is uniformly persistent with respect to (X0, ∂X0)
in the sense that there is a positive constant ζ > 0 such that every solution
(T (t), T ∗(t),M(t),M∗(t),MB(t),M
∗
B(t), V (t), VB(t))
of (4.1) with
(T (0), T ∗(0),M(0),M∗(0),MB(0),M
∗
B(0), V (0), VB(0)) ∈ X0
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satisfies
lim inf
t→∞
u(t) ≥ ζ, ∀ u = T ∗, M∗, M∗B, V, VB. (4.12)
Furthermore, system (4.1) admits at least one (componentwise) positive equi-
librium.
PROOF. Part (i). Assume that R0 < 1. It then follows from Lemma 2 (iii)
that s(J) < 0. Thus, there exists a sufficiently small positive number ρ0 such that
s(Jρ0) < 0 (see, e.g., [38, Section II.5.8]), where
Jρ0 =

−δ 0 0 Φbβ(T̂ + ρ0) 0
0 −(ϕ+ δM) ψ ΦbβM(M̂ + ρ0) 0
0 ϕ −(ψ + δM) 0 ΦπbβM(M̂B + ρ0)
Φpp ΦppM 0 −c 0
0 0 ΦπppM 0 −c

has non-negative off-diagonal elements, and Jρ0 is irreducible. From the first, third,
and fifth equations of system (4.1), together with positivity of solutions, it follows
that
dT
dt
≤ λ− dT, (4.13)
and 
dM
dt
≤ λM − (ϕ+ dM)M + ψMB,
dMB
dt
≤ ϕM − (ψ + dM)MB.
(4.14)
By the comparison principle and Lemma 1, we see that
lim sup
t→∞
T (t) ≤ T̂ , lim sup
t→∞
(M(t),MB(t)) ≤ (M̂, M̂B).
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It follows that there is a t1 > 0 such that
T (t) ≤ T̂ + ρ0, M(t) ≤ M̂ + ρ0, MB(t) ≤ M̂B + ρ0, ∀ t ≥ t1. (4.15)
In view of (4.15) and system (4.1), we see that
dT ∗
dt
≤ Φbβ(T̂ + ρ0)V − δT ∗, ∀ t ≥ t1,
dM∗
dt
≤ ΦbβM(M̂ + ρ0)V + ψM∗B − (ϕ+ δM)M∗, ∀ t ≥ t1,
dM∗B
dt
≤ ΦπbβM(M̂B + ρ0)VB + ϕM∗ − (ψ + δM)M∗B, ∀ t ≥ t1,
dV
dt
= ΦppT
∗ + ΦppMM
∗ − cV, ∀ t ≥ t1,
dVB
dt
= ΦπppMM
∗
B − cVB, ∀ t ≥ t1.
(4.16)
Consider the following auxiliary system
dT ∗
dt
= Φbβ(T̂ + ρ0)V − δT ∗, ∀ t ≥ t1,
dM∗
dt
= ΦbβM(M̂ + ρ0)V + ψM
∗
B − (ϕ+ δM)M∗, ∀ t ≥ t1,
dM∗B
dt
= ΦπbβM(M̂B + ρ0)VB + ϕM
∗ − (ψ + δM)M∗B, ∀ t ≥ t1,
dV
dt
= ΦppT
∗ + ΦppMM
∗ − cV, ∀ t ≥ t1,
dVB
dt
= ΦπppMM
∗
B − cVB, ∀ t ≥ t1.
(4.17)
Since Jρ0 has non-negative off-diagonal elements and Jρ0 is irreducible, it follows that
s(Jρ0) is simple and associates a strongly positive eigenvector ṽ ∈ R5 (see, e.g., [66,
Theorem A.5]). For any solution (T (t), T ∗(t),M(t),M∗(t),MB(t),M
∗
B(t), V (t), VB(t))
of (4.1) with nonnegative initial value
(T (0), T ∗(0),M(0),M∗(0),MB(0),M
∗
B(0), V (0), VB(0)),
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there is a sufficiently large b > 0 such that
(T ∗(t1),M
∗(t1),M
∗
B(t1), V (t1), VB(t1)) ≤ bṽ
holds. It is easy to see that U(t) := bes(J
0
ρ0
)(t−t1)ṽ is a solution of (4.17) with U(t1) :=
bṽ . By the comparison principle [66, Theorem B.1], it follows that
(T ∗(t),M∗(t),M∗B(t), V (t), VB(t)) ≤ bes(Jρ0 )(t−t1)ṽ, ∀ t ≥ t1.
Since s(Jρ0) < 0, it follows that
lim
t→∞
(T ∗(t),M∗(t),M∗B(t), V (t), VB(t)) = (0, 0, 0, 0, 0).
It then follows that the equations for T (t) and (M(t),MB(t)) in (4.1) are
asymptotic to (4.4) and (4.5), respectively. By the theory for asymptotically au-
tonomous semiflows (see, e.g., [70, Corollary 4.3]) and Lemma 1, it follows that
lim
t→∞
T (t) = T̂ , lim
t→∞
(M(t),MB(t)) = (M̂, M̂B).
Part (i) is proved.
Part (ii). Assume that R0 > 1. It then follows from Lemma 2 (ii) that
s(J) > 0. Suppose Π(t)P is the solution maps generated by system (4.1) with initial
value P . By Theorem 1, we see that system {Π(t)}t≥0 admits a global attractor in
R8+ . Now we prove that {Π(t)}t≥0 is uniformly persistent with respect to (X0, ∂X0).
By Lemma 3, it follows that both R8+ and X0 are positively invariant. Clearly, ∂X0
is relatively closed in R8+ .
Let M∂ := {P ∈ ∂X0 : Π(t)P ∈ ∂X0, ∀ t ≥ 0} and ω(P ) be the omega limit
set of the orbit O+(P ) := {Π(t)P : t ≥ 0} . We next prove the following claims.
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Claim 1: ω(P ) = {E0}, ∀ P ∈M∂ .
Since P ∈M∂ , we have Π(t)P ∈M∂, ∀ t ≥ 0. Next, we show that
(T ∗(t),M∗(t),M∗B(t), V (t), VB(t)) = (0, 0, 0, 0, 0), ∀ t > 0. (4.18)
Assume that (4.18) is not true. Then there exists τ0 > 0 such that
(T ∗(τ0),M
∗(τ0),M
∗
B(τ0), V (τ0), VB(τ0)) 6= (0, 0, 0, 0, 0).
Then the irreducibility of the cooperative matrix (4.11) implies that
(T ∗(t),M∗(t),M∗B(t), V (t), VB(t)) 0, ∀ t > τ0,
which contradicts the fact that Π(t)P ∈ M∂, ∀ t ≥ 0, and hence, (4.18) is true. By
(4.18), it follows that the equations for T (t) and (M(t),MB(t)) in (4.1) satisfies (4.4)
and (4.5), respectively. By Lemma 1, it follows that
lim
t→∞
T (t) = T̂ , lim
t→∞
(M(t),MB(t)) = (M̂, M̂B).
Claim 1 is proved.
Since s(J) > 0, there exists a sufficiently small positive number σ0 such that
s(Jσ0) > 0 (see, e.g., [38, Section II.5.8]), where
Jσ0 =

−δ 0 0 Φbβ(T̂ − σ0) 0
0 −(ϕ+ δM) ψ ΦbβM(M̂ − σ0) 0
0 ϕ −(ψ + δM) 0 ΦπbβM(M̂B − σ0)
Φpp ΦppM 0 −c 0
0 0 ΦπppM 0 −c

has non-negative off-diagonal elements and Jσ0 is irreducible.
56
Claim 2: E0 is a uniform weak repeller for Π(t) in the sense that
lim sup
t→∞
‖Π(t)P − E0‖ ≥ σ0, ∀ P ∈ X0.
Suppose, by contradiction, there exists P0 ∈ X0 such that
lim sup
t→∞
‖Π(t)P0 − E0‖ < σ0.
Thus, there exists t2 > 0 such that
T (t) ≥ T̂ − σ0, M(t) ≥ M̂ − σ0, MB(t) ≥ M̂B − σ0, ∀ t ≥ t2. (4.19)
In view of (4.19) and system (4.1), we see that
dT ∗
dt
≥ Φbβ(T̂ − σ0)V − δT ∗, ∀ t ≥ t2,
dM∗
dt
≥ ΦbβM(M̂ − σ0)V + ψM∗B − (ϕ+ δM)M∗, ∀ t ≥ t2,
dM∗B
dt
≥ ΦπbβM(M̂B − σ0)VB + ϕM∗ − (ψ + δM)M∗B, ∀ t ≥ t2,
dV
dt
= ΦppT
∗ + ΦppMM
∗ − cV, ∀ t ≥ t2,
dVB
dt
= ΦπppMM
∗
B − cVB, ∀ t ≥ t2.
(4.20)
Consider the following auxiliary system
dT ∗
dt
= Φbβ(T̂ − σ0)V − δT ∗, ∀ t ≥ t2,
dM∗
dt
= ΦbβM(M̂ − σ0)V + ψM∗B − (ϕ+ δM)M∗, ∀ t ≥ t2,
dM∗B
dt
= ΦπbβM(M̂B − σ0)VB + ϕM∗ − (ψ + δM)M∗B, ∀ t ≥ t2,
dV
dt
= ΦppT
∗ + ΦppMM
∗ − cV, ∀ t ≥ t2,
dVB
dt
= ΦπppMM
∗
B − cVB, ∀ t ≥ t2.
(4.21)
Since Jσ0 is irreducible and has non-negative off-diagonal elements, it follows that
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s(Jσ0) is simple and associates a strongly positive eigenvector ũ ∈ R5 (see, e.g., [66,
Theorem A.5]). By Lemma 3, it follows that
(T ∗(t2),M
∗(t2),M
∗
B(t2), V (t2), VB(t2)) 0.
Thus, there is a positive number ς > 0 such that
(T ∗(t2),M
∗(t2),M
∗
B(t2), V (t2), VB(t2)) ≥ ςũ
holds. It is easy to see that W (t) := ςes(Jσ0 )(t−t2)ũ is a solution of (4.21) with
W (t2) := ςũ . By the comparison principle [66, Theorem B.1], it follows that
(T ∗(t),M∗(t),M∗B(t), V (t), VB(t)) ≥ ςes(Jσ0 )(t−t2)ũ, ∀ t ≥ t2.
Since s(Jσ0) > 0, it follows that
lim
t→∞
T ∗(t) = lim
t→∞
M∗(t) = lim
t→∞
M∗B(t) = lim
t→∞
V (t) = lim
t→∞
VB(t) =∞.
This contradiction proves the claim 2.
From the above claims, it follows that any forward orbit of Π(t) in M∂ con-
verges to E0 which is isolated in R8+ and W s(E0) ∩ X0 = ∅ , where W s(E0) is the
stable set of E0 (see [64]). It is obvious that there is no cycle in M∂ from E0 to E0 .
By [71, Theorem 4.6] (see also [82, Theorem 1.3.1] and [33, Theorem 4.3 and Remark
4.3]), we conclude that system (4.1) is uniformly persistent with respect to (X0, ∂X0)
in the sense that there is a positive constant ζ > 0 such that (4.12) holds.
By [81, Theorem 2.4] (see also [82, Theorem 1.3.7]), system (4.1) has at least
one equilibrium
(Ť , Ť ∗, M̌ , M̌∗, M̌B, M̌
∗
B, V̌ , V̌B) ∈ X0,
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and hence, Ť ∗ > 0, M̌∗ > 0, M̌∗B > 0, V̌ > 0, and V̌B > 0. Furthermore, we see
that
Ť =
λ
ΦbβV̌ + d
,
and (M̌, M̌B) satisfies
λM − ΦbβM V̌ M − ϕM + ψMB − dMM = 0,
ϕM − ψMB − ΦπbβM V̌BMB − dMMB = 0,
(4.22)
From (4.22), it is not hard to see that M̌ > 0 and M̌B > 0. Thus,
(Ť , Ť ∗, M̌ , M̌∗, M̌B, M̌
∗
B, V̌ , V̌B)
is a (componentwise) positive equilibrium of system (4.1). This completes the proof
of Part (ii). tu
Numerical Simulations
In the following sections we show the numerical simulations of the plasma
viral load (PVL) and the brain viral load (BVL) under different treatment protocols.
We consider how the different protocols affect the time the viral loads take to reach
undetectable levels. We first examine whether the CPE score reduces treatment time
in the plasma and what effect it has on the reduction time for the brain viral load.
Next, we explore how the slope of the dose-response curve affects the date of viral
undetectability. Then, we analyze the effect of larger numbers of drugs in a given
ART regimen, and finally we examine if the initial treatment day affects the average
day the PVL and BVL clear below measurable levels. For all simulations we consider
a detected viral load to be fifty copies of viral RNA per µL , which is the standard
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lower limit to measure HIV according to current assays [1].
Effect of the CPE Score
To better understand the effect of the CPE score on the overall treatment
of HIV, we considered its effect on the time that the PVL and the BVL reduce to
undetected levels in the presence of constant treatment. In Figure 17 we show the
average time the viral loads in the brain and the plasma take to become undetectable
depending on the CPE score of an ART regimen with a single drug. Treatment was
assumed to begin after a steady-state viral load was achieved (∼250 dpi) and we
considered a single RTI and a single PI.
Figure 17: The average time the viral loads in the plasma (blue) and the brain (green)
become undetectable depending on the mean CPE score of the ART regimen with
either a single RTI (left) or PI (right).
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We clearly observe that the CPE score has no effect on the plasma viral load,
as the average number of days for the PVL to become undetectable remains constant
despite the CPE score or the drug type (RTI or PI). However, even with one drug
present, we observe that the CPE score affects the number of days to viral unde-
tectability for a PI differently than it does for an RTI. In particular, as the CPE
score increases for a PI, the number of days for the BVL to reach undetectable levels
decrease (≈ 10 days to ≈ 3 days). There is no observed effect of the CPE score on
the BVL if an ART protocol includes a only a single RTI. Hence, the BBB affects
single-drug protocols with PIs more than RTIs.
To analyze this effect further we considered ART with two drugs. We present
the model simulations of the number of days to viral undetectability in the PVL and
BVL in Figure 18. Treatment was initiated after steady-state infection had occurred
(250 dpi) and we considered two PIs, 2 RTIs, and a combination of one PI and one
RTI.
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Figure 18: Average days to viral undetectability in the PVL (left column) and BVL
(right column) depending on the CPE scores for two PIs (top row), two RTIs (bottom
row) and one RTI and one PI (middle row).
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Similar to the treatments with a single drug we see no discernible effect of
the CPE score on the PVL with two drugs. However, we observe a strong effect of
the CPE score on the days for the BVL to become undetectable in the presence of
constant treatment with two drugs. For ART with two PIs we observe that as CPE
increases for either drug, the days for the virus to become undetected decreases (≈ 9
days v. ≈ 1 day). Furthermore, if ART includes an RTI and a PI we note that
as the CPE score increase for the PI, the days to an undetectable BVL decreases,
however the CPE score for the RTI shows no effect on the days to undetectability in
the BVL. In fact, if treatment includes only two RTIs we do not observe an effect
of the CPE score on the overall time to viral undetectability. This suggests that
protease inhibitors with higher CPE scores should be considered more than RTIs to
better control HIV in the brain.
Effect of the Slope of the dose-response Curve
Since the CPE score was more effective for PIs, which generally possess higher
slopes of the dose-response curve than RTIs, in this section we used our model (4.1)
to explore the influence of the slope of the dose-response curve on the date viral RNA
becomes undetectable. We first considered constant treatment with exactly one drug.
In Figure 19 we plotted the average date the virus in the plasma and the brain takes to
become undetectable depending on the slope of the dose-response curve. Treatment
was set to begin after a steady-state viral load was achieved in the brain and the
plasma (250 dpi), and we varied slopes between zero and 5. As per experimental
evidence [61], we considered any drug whose slope, m , is greater than 1.9 to be a
protease inhibitor, and a drug with m ≤ 1.9 is considered to be an RTI (see Table 4).
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A single-drug ART protocol was considered with a low CPE score and a high CPE
score (CPE= 1 vs. CPE= 4).
We observe that if m ≤ 1.9 (RTI) then the PVL becomes undetectable after
at least 40 days, whereas if m > 1.9 (PI) then the PVL reaches undetectable levels
within a single day. The number of days the BVL takes to reach undetectable levels
also decreases as the slope of the dose-response curve increases, however this reduction
is significantly less than that observed in the PVL (≈ 40 days less compared to ≈ 6
days less). Interestingly, for low slopes corresponding to an RTI, we note that the
PVL becomes undetectable several weeks after the BVL becomes undetectable, and
that this behavior switches for the slope corresponding to a protease inhibitor. This
switch occurs regardless of the CPE score of the drug, reinforcing the observation
from the previous section that RTIs are less effective against the PVL.
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Figure 19: Model simulations of the total time it takes the viral load in the plasma
to become undetectable depending on the slope of the dose-response curve. If the
slope, m , was greater than 1.9 that drug was taken to be a PI, whereas if m ≤ 1.9
we considered that drug an RTI.
To examine the effect of the dose-response curve slope further we considered
ART that included both an RTI and a PI. RTIs and PIs were considered with high
and low CPE scores each and we predicted the total days to viral undetectability
in the PVL and the BVL in Figures 20 and 21, respectively. We note that in all
cases the BVL and the PVL measured little to no difference in the number of days
before they become undetectable, suggesting that once multiple drugs are present in
ART, the slope of the dose-response curve does not change the total number of days
to viral undetectability. However, for ART with two drugs, even if the slopes of the
dose-response curves are low, the average number of days to viral undetectability is
much less (≈ 10 days compared to ≈ 40 days). In particular we observe that if both
65
an RTI and a PI are present in ART, the BVL reaches undetected levels at least three
days after the PVL becomes undetectable.
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Figure 20: The total days to viral undetectability in the PVL depending on the slopes
of the dose-response curve of both an RTI and a PI. PIs with a CPE score of one (top
row) and four (bottom row) were considered with RTIs with a CPE score of one (left
column) and four (right column).
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Figure 21: The total days to viral undetectability in the PVL depending on the slopes
of the dose-response curve of both an RTI and a PI. PIs with a CPE score of one (top
row) and four (bottom row) were considered with RTIs with a CPE score of one (left
column) and four (right column).
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Table 3: Fixed parameters for all monkeys, arithmetic mean data, median data, and
geometric mean data.
Model Values
Initial Values
Name Symbol Value Source
Initial uninfected T-cells T0 38700 Vaidya et al. [73]
Initial infected T-cells T ∗0 0 Kumar et al. [45]
Initial uninfected plasma Macrophages M0 1463000 Haney et al. [30]
Initial infected plasma Macrophages M∗0 0 Kumar et al. [45]
Initial uninfected CSF Macrophages MB0 20000 Haney et al. [30]
Initial infected CSF Macrophages MB0 0 Kumar et al. [45]
Initial plasma free Virions V0 200 Kumar et al. [45]
Initial CSF free Virions VB0 0 Kumar et al. [45]
Parameter Values
Name Symbol Value Source
Death rate for uninfected T-cells d 0.01 (day−1) Stafford et al. [67]
Death rate for uninfected Macrophages dM 0.00185 (day
−1) Prinz et al. [53]
Recruitment rate for T-cells λ 387 (day−1) Calculated
Recruitment rate for Macrophages λM 2743.55 (day
−1) Calculated
Viral production from infected T-cells p 50000 (day−1) Chen et al. [16]
Viral production from infected macrophages pM 1000 (day
−1) Schwartz et al. [60]
Viral clearance rate c 23 (day−1) Ramratnam et al. [54]
T-cell infection rate β 3.5830E-8 (ml/day) Estimated
Death rate for infected T-cells δ 1.4551 (day−1) Estimated
Macrophage infection rate βM 8.653E-10 (ml/day) Estimated
Death rate for infected macrophages δM 0.2060 (day
−1) Estimated
Rate of macrophage entry into the brain ϕ 0.03876 (day−1) Estimated
Rate of macrophage exit from the brain ψ 8.9953 (day−1) Estimated
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Table 4: Chart of drugs Emacs score and CPE scores.
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Effect of Multiple Drugs
In the previous section our model predictions showed that more drugs in a
cART regimen led to less time for the virus to become undetectable. However, it is
unclear whether this correlation is stronger for the brain or for the plasma. To better
understand this we examined the effect of ART with three or more drugs on the days
to viral undetectability in the CSF and the plasma. Random slopes between 0 and 5
were taken and paired with random CPE scores between 0 and 5. Drug types were
categorized by the slope of the dose-response curve (RTI if m ≤ 1.9, PI if m > 1.9).
Treatment was assumed to be constant and initiated after the viral loads reached a
steady-state (≈ 250 dpi). In Figure 22 we present the boxplots of the days for the
PVL and BVL to reach undetectable levels after simulations of 15,000 random drug
combinations of at least three drugs.
In all cases we observe that ART with multiple drugs reduces the PVL to
undetectable levels before the BVL becomes undetectable. However, we note about a
large number of outliers among the PVL implying some uncertainties. This is likely
because we chose uniformly distributed random slopes between 0 and 5, which has a
greater likelihood of selecting slopes corresponding to PIs (m > 1.9).
We note that the number of drugs in a treatment protocol affects the reduction
time of the BVL. Specifically, the median days for the BVL to become undetectible
decreases (≈ 7 dpi v. ≈ 0.5 dpi) as the number of drugs in a treatment protocol
increases from three to five. We also observe that for drug regimens with a higher
number of drugs, viral suppression in the plasma may not indicate viral suppression
in the brain. This implies that the BBB potentially poses a stronger effect on multiple
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Figure 22: Mean time for the virus to become undetectable (in days) depending on
the number of drugs in an ART regimen.
drugs protocols than on smaller combinations of ART.
Effect of Treatment Initiation Time
In Figure 23 we present the predicted time in days post-infection that the
plasma viral load and the brain viral load achieve undetectable levels depending on
the initial time of treatment. Treatment was assumed to be constant and includes a
single RTI or PI with a corresponding CPE score of either one or four. The time of
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treatment initiation varied between one and 300 days post-infection (dpi).
Figure 23: The average time (in days) it takes for viral RNA copies to become
undetectable (< 50 copies per µL [1]) in the plasma (blue) and the brain (green) in
the presence of constant treatment from one RTI (top row) or from a PI (bottom row)
with a low CPE score (left column) and high CPE score (right column), depending
on the initial date of treatment.
We observe that if treatment does not begin after steady-state infection, it is
clear that the earliest initiated treatment (< 3 dpi) is ideal as it can prevent infection
from reach detectable levels in the brain. This is consistent with previous studies
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[17, 75]. Furthermore, our simulations suggest that outside of early treatment, in
general, the time for the PVL and BVL to reach undetectable levels varies significantly
within the first 100 days post-infection. For instance, if treatment begins during the
second week post-infection we observe that the virus is detectable in both the plasma
and the brain for longer (15 − 20 dpi) than for any other initial treatment time.
If constant ART is initiated between eight and ten weeks post-infection, the total
time before viral undetectability is significantly less than any other time of treatment
initiation (<5 dpi in the brain, ≈ 8 dpi in the plasma). Treatment initiation after a
viral steady-state has been achieved were not observed to significantly affect the time
for the virus to attain undetectable levels.
When we compare ART with PIs and RTIs by varying the time of treatment
initiation we observe similar dynamics from the previous sections. Specifically, we
note that treatment with a PI is extremely effective at reducing the PVL, but less
effective at reducing the BVL, whereas ART with an RTI reduces the BVL consis-
tently more efficiently than the PVL. We note that in some cases if the CPE score is
high then the time of treatment initiation affects whether the BVL or PVL becomes
undetectable first. We do not observe this behavior when varying treatment initiation
time for drugs associated with low CPE scores.
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CHAPTER 5
STOCHASTIC MODEL OF HIV INFECTION IN THE BRAIN
In this chapter we develop a stochastic model to analyze stochastic effects
on the viral dynamics of HIV-1 in the brain. We also compare the predictions of
our model to those of our deterministic model. We then examine the computed
reaction propensity functions which indicate likely infection behavior. Furthermore,
we analyze the overall probability distributions during the most likely infection time
predicted by our model.
Introduction
The models developed in chapters 3 and 4 are deterministic models to study
the effect of the brain on the comprehensive viral dynamics of HIV-1. Both models
illustrated some uncertainty. This uncertainty and the randomness found in biological
events suggested a need to develop stochastic model of HIV-1 in the brain. Many
stochastic models have been developed to study HIV [80, 20, 37, 47, 52, 69, 72], but
these focus on early viral dynamics within the plasma. None consider the brain in
their models. There is clearly a need to examine the stochastic effect of the BBB on
the viral dynamics of HIV in the brain.
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Model Development
Choice of stochastic modeling technique
There are several methods for deriving a stochastic model from a determinis-
tic one. Some of the earliest numerical approximation methods were introduced by
Gillespie in 2001 [25], and improved upon later by introducing a faster method for
simulations. Methods used to study HIV-1 stochastically range from introducing a
random perturbation into any number of parameters [20], complex networking [62],
and most commonly a drift function proposed by Allen et al. [80]. For any of the
latter methods one must prove the non-negativity of the solutions. However, it was
observed by Cresson and Sonner [19] that there are some characteristics of deter-
ministic models that cannot be proven to achieve full non-negativity of solutions. In
particular, from the system (3.1) we observe that the interaction function
d
dT
= λ− βV T − dT,
contains a constant term. It follows from Corollary 3.1 of [19] that any stochas-
tic model derived from this system using the method in [80] fails to preserve non-
negativity. Thus, we attempted the algorithm defined in [25], but due to the large
volume of cells in the macrophage population we observed extremely small time-steps,
demanding too large a computer cost for practical use. In order to capture the near-
est approximate biological phenomenon, we used the τ -leap method from [15] which
uses Poisson random variables to approximate large enough time-steps for a 100 day
simulation to occur in a reasonable computation time.
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Stochastic Model
To formulate the stochastic model we represent each cell and virus compart-
ments from the deterministic model described in Chapter 3 as a continuous random
variable. We then let ~X = [T, T ∗,M,M∗,MB,M
∗
B, V, VB]
tr be a continuous ran-
dom vector such that for a sufficiently small change in time (∆t), the possible state
changes, ∆~X = ~X(t + ∆t) − ~X(t), are based on the deterministic model 3.1. As an
example, the state change vector ∆~X8 = [−1, 0, 0, 0, 0, 0, 0, 0, 0]tr represents the death
of an uninfected CD4+ T cell. The state changes (called reactions) for the stochastic
model can be differentiated into four categories: cell births (Ri for i = 1, . . . , 4),
deaths (Ri for i = 5, . . . , 12), infections (Ri for i = 13, 14, 15), and transports
through the blood-brain barrier (Ri for i = 16, . . . , 19). There are 19 reactions in all
and the rates and state change vectors are given in Table 5. A schematic diagram of
the model is present in Figure 24. 500 model simulations for 100 days post-infection
were performed using Python 3.5.2, and the Stochpy package. All parameter values
are positive and the rates are given in Table 6.
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Figure 24: Schematics for the stochastic model.
Results
In the following sections we show the results of 500 numerical simulations for
100 days for each cell type. We first show the computer average trajectories and their
respective calculated deterministic predictions. We next examine the average propen-
sity functions for each possible reaction. Finally, we show the average distribution
for each cell.
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Table 5: Possible state changes during ∆t .
Category Ri State change vector (∆~X
tr
i ) Probability Description
Births
1 [1,0,0,0,0,0,0,0] λ Birth of a CD4+ T cell
2 [0,0,1,0,0,0,0,0] λM Birth of a plasma macrophage
3 [0,0,0,0,0,0,1,0] p+ pM Production of a free plasma virion
4 [0,0,0,0,0,0,0,1] pM Production of a free brain virion
Deaths
5 [-1,0,0,0,0,0,0,0] d Uninfected CD4+ T cell
6 [0,-1,0,0,0,0,0,0] δ Infected CD4+ T cell death
7 [0,0,-1,0,0,0,0,0] dM Uninfected plasma macrophage death
8 [0,0,0,-1,0,0,0,0] δM Infected plasma macrophage death
9 [0,0,0,0,-1,0,0,0] dM Uninfected brain macrophage death
10 [0,0,0,0,0,-1,0,0] δM Infected brain macrophage death
11 [0,0,0,0,0,0,-1,0] c Clearance of free plasma virion
12 [0,0,0,0,0,0,0,-1] c Clearance of free brain virion
BBB
Infections
13 [-1,1,0,0,0,0,-1,0] βV T Infection of a target CD4+ T cell
14 [0,0,-1,1,0,0,-1,0] βMVM Infection of a plasma macrophage
15 [0,0,0,0,-1,1,0,-1] βVBMB Infection of a brain macrophage
BBB
Transits
16 [0,0,-1,0,1,0,0,0] ϕ Uninfected macrophage transport into the CSF
17 [0,0,1,0,-1,0,0,0] ψ Uninfected macrophage transport into the plasma
18 [0,0,0,-1,0,1,0,0] ϕ Infected macrophage transport into the CSF
19 [0,0,0,1,0,-1,0,0] ψ Infected macrophage transport into the plasma
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Table 6: Parameter values for deterministic model.
Model Values
Initial Values
Name Symbol Value Source
Initial uninfected T-cells T0 38700 Vaidya et al. [73]
Initial infected T-cells T ∗0 0 Kumar et al. [45]
Initial uninfected plasma Macrophages M0 1463000 Haney et al. [30]
Initial infected plasma Macrophages M∗0 0 Kumar et al. [45]
Initial uninfected CSF Macrophages MB0 20000 Haney et al. [30]
Initial infected CSF Macrophages M∗B0 0 Kumar et al. [45]
Initial plasma free Virions V0 200 Kumar et al. [45]
Initial CSF free Virions VB0 0 Kumar et al. [45]
Parameter Values
Name Symbol Value Source
Death rate for uninfected T-cells d 0.01 (day−1) Stafford et al. [67]
Death rate for uninfected Macrophages dM 0.00185 (day
−1) Prinz et al. [53]
Recruitment rate for T-cells λ 387 (day−1) Calculated
Recruitment rate for Macrophages λM 2743.55 (day
−1) Calculated
Viral production from infected T-cells p 50000 (day−1) Chen et al. [16]
Viral production from infected macrophages pM 1000 (day
−1) Schwartz et al. [60]
Viral clearance rate c 23 (day−1) Ramratnam et al. [54]
T-cell infection rate β 3.5830E-8 (ml/day) Estimated
Death rate for infected T-cells δ 1.4551 (day−1) Estimated
Macrophage infection rate βM 8.653E-10 (ml/day) Estimated
Death rate for infected macrophages δM 0.2060 (day
−1) Estimated
Rate of macrophage entry into the brain ϕ 0.03876 (day−1) Estimated
Rate of macrophage exit from the brain ψ 8.9953 (day−1) Estimated
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Comparison to deterministic model
In this section we used the stochastic model to compare the solutions from the
described deterministic model (3.1). In Figure 25 we present the average trajectories
for all eight cell types studied. Error bars of one standard deviation from the mean
trajectories are shown and the predicted deterministic model values are superimposed
on each graph. We observe that except for the uninfected brain macrophages that
each predicted trajectory from the deterministic cell values lies within one standard
deviation of the average stochastic simulated trajectories, suggesting the stochastic
simulations capture the deterministic model. Hence the proposed stochastic model is
valid and reasonable.
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Figure 25: Average trajectories predicted by the stochastic (SDE) model (solid line)
compared to the predicted trajectories from the deterministic (ODE) model (dashed
line) with error bars of one standard deviation.
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Propensity Functions
In the following subsections, we analyze the calculated average daily propen-
sity values for each reaction. Gillespie [25] defines, for a well-stirred system, the
probability that a reaction Ri fires in the next time step, dt , to be ai(~x) dt , where
ai(~x) is the propensity function. Thus, a propensity function is closely related to
the probability of a reaction firing. In the τ -leap stochastic simulation algorithm, a
propensity function measures how many reactions will likely occur over a given time
interval. It is important to note that a propensity value is not a probability, but as
a general rule the higher the propensity value, the likelier that reaction will occur.
By analyzing propensity values we can predict when specific reactions, such as new
brain macrophage infections, are most likely to fire. Since propensity functions are
defined based on cell populations the absolute value of a propensity function is less
informative than the day the max value occurs and the length of time a propensity
functions remains near a peak value. That is, the shape of a propensity function does
not depend on cell populations, thus qualitative results drawn from the shape of a
propensity curve provide more information than exact function values.
Infection Reactions
In Figure 26 we plot the mean propensity values at a given time t of the
infection reactions (Ri for i = 5, 6, 7) from 500 simulations.
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Figure 26: Predicted per day average propensity values for the reactions of CD4+ T
cell infections (left), infection of macrophages in the plasma (center), and infection
of macrophages in the brain (right).
Each reaction propensity function follows a similar curve, but it is clear that
the most likely time for new cell infection is early (∼ 2 weeks post-infection), as the
propensity functions for the reactions involving new infections peak within the first
two weeks. However, it does not appear that a large number of infection reactions
are particularly likely outside of the first two weeks, which suggests that new viral
infections may not be as high as the first two weeks.
To better understand which infection reactions maintain their highest likeli-
hood longer, we calculated the number of days a reaction’s propensity function was
within 80% of its peak value and plotted the results in Figure 27. We observe that
the infection of plasma cells (T and M ) reach their highest likelihoods first before
the brain infection reactions become most likely (6-8 dpi vs. 10-14 dpi). This sug-
gests that viral infection in the brain depends on viral infection transporting from
the plasma, which is consistent with findings from previous studies [50, 51, 59, 79].
Furthermore we observe that the infection reaction in the brain sustains its high like-
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lihood for at least twice as long (4 days vs. 1-2 days) as infection reactions in the
plasma. Thus there is a greater window of high infection probability in the brain
compared to that in the plasma.
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Figure 27: The days in which the reaction propensity functions are within 80% of
their max values for infections of uninfected cells.
Viral Production
In this subsection we consider the reaction propensity functions for the pro-
duction of free virions in the plasma (R3 ) and in the brain (R4 ). We plot the average
propensity functions in Figure 28. We first note that the likelihood of production of
free virions in both the brain and the plasma vary considerably depending on time,
and in a similar manner as the propensity functions for infections varies. There is a
maximum likelihood that occurs during early infection (around the first two weeks).
We also note that the plasma viral production reaction has low propensity values for
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much of the infection time, whereas the likelihood that free virions are produced in
the brain appears for a longer duration.
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Figure 28: Predicted per day average propensity values for reactions involving pro-
duction of free virions in the plasma (left) and in the CSF (right).
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Figure 29: The days in which the reaction propensity functions are within 80% of
their max values for the production of free virions in the plasma (V ) and in the CSF
(VB ).
To analyze this apparent sustained higher probability we plot the number of
days that the reactions of viral production in the plasma and the brain maintain at
least 80% of their peak propensity values in Figure 29. We observe that the reaction
of viral production in the brain reaches its max propensity later (10 dpi vs. 6 dpi)
and sustains near-max likelihood longer (4 dpi vs. 2 dpi) than the reaction of viral
production in the plasma. This suggests that similar to viral infection reactions, there
is a larger time interval for which the virus brain is likely to replicate compared to
that in the plasma.
Most Likely Reactions
Although propensity functions are defined based on cell populations, the high-
est propensity value across the entire set of reactions implies that more firings of
86
that reaction are likely to occur in a given time interval. Thus we can analyze the
most likely reaction at a given time for the entire system. We present the most likely
reactions to fire in Table 7 defined by the maximum propensity value at a given time,
t . We observe that the highest propensity values revolve around only three reactions:
initial transfer of macrophages into the brain, the production of plasma viruses, and
the clearance of plasma virions. Specifically, plasma viral clearance becomes more
probable a reaction after the first week, but during the seventh week post infection
we observe a greater likelihood of viral infection. This is immediately followed by
a brief period of more likely viral clearance, and then another month which viral
production again is most likely of all reactions. This suggests that most of the cell
reactions that occur during infection are the production and clearance of free virions
in the plasma. Since there is a significantly higher amount of infected cells producing
free virions in the plasma compared to infected cells in the brain, this reaction may
be expected.
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Table 7: Predicted likeliest reaction to occur at any given time t .
Highest Average Propensity Value
t in days post-infection Reaction
0-2 Macrophage transit into the CSF
2-6 Production of plasma free virions
8-52 Clearance of plasma free virions
52-54 Production of plasma free virions
56-58 Clearance of plasma free virions
60-92 Production of plasma free virions
94-100 Clearance of plasma free virions
Average State Distributions
Since propensity functions are strongly related to cell populations, in this sec-
tion we considered the distributions of cell populations during the days the infection
and viral production reactions are most likely to occur. Normal curve fittings to the
state probability distributions of infected CD4+ T cells, infected macrophages in the
plasma and the brain, and free virions in the plasma and in the brain for 6, 8, and
12 days post-infection are shown in Figure 30. To better analyze these distributions
we charted the respective variances of each distribution in Table 8.
We observe that for infected CD4+ T cells there is more stochastic fluctuation
(Var ∼ 4 × 105 vs. Var ∼ 1 × 105 ) when T cell infection is likeliest (6 dpi) than
afterwards (12 dpi). A similar phenomenon was observed for free virions in the plasma
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(Var ∼ 2× 1012 at 6 dpi vs. Var ∼ 7× 1011 at 12 dpi). These findings are consistent
with results from stochastic models presented by Allen et al. [80].
For infected macrophages we observe that the stochastic variance is greater
(∼ 87% more) during the second week (12 dpi) compared to the first week (6 dpi).
This effect is independent of whether the infected macrophages reside in the brain or
in the plasma. We note that the free virions in the brain also have a wider distribution
(Var ∼ 1.5× 107 vs. Var ∼ 1.7× 106 ) at 12 days post-infection compared to 6 days
post-infection. This suggests that the stochastic fluctuation experienced in the brain
is primarily related to the infected macrophages. In fact, the days in which the
infection reaction propensity functions are near max values correspond to the days
that the stochastic fluctuation is greatest for infected cells and free virions.
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Figure 30: Normal curve fittings to approximate distributions for infected T cells
(top row), infected macrophages in the plasma (second row, left column) and in the
brain (second row, right column), as well as free virions in the plasma (bottom row,
left column) and in the brain (bottom row, right column) for days 6, 8, and 12 post-
infection.
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Table 8: Table of variances of the state probability distributions for infected cells and
free virions on days 6, 8, and 12 post-infection.
Distribution Variances
Cell Type 6 DPI 8 DPI 12 DPI
T ∗ 3.9291×105 4.98×105 1.2248×105
M∗ 2.440×106 1.5325×107 1.7015×107
M∗B 996.65 6.43×103 7.8889×103
V 1.9437×1012 2.7885×1012 6.9649×1011
VB 1.722×106 1.2024×107 1.4719×107
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CHAPTER 6
CONCLUSIONS AND DISCUSSION
HIV-1 remains a major public health challenge and one of the leading causes of
death worldwide [4]. While HIV-1 is one of the most studied diseases, viral dynamics
in the brain remains one of the least studied aspects of the disease. In particular,
the transport of the virus through BBB, the presence of ongoing viral replication
in the brain, and the lack of transport of ART drugs through the BBB are poorly
understood. In this dissertation, we develop models to address these issues.
The model we developed in chapter 3 can explain the experimental viral load
data in the plasma and the CSF from SIV/SHIV infected macaques. Using our
model and experimental data we estimated key parameters, including those related
to the BBB. In addition, we performed thorough sensitivity analysis, including the
one using Latin hypercube sampling technique, to examine the robustness of the
dynamics described by our model.
Our model predicts that the entry of HIV virus and/or viral protein via
macrophages crossing the BBB is time-varying in nature and the rate of entry may
depend on the virus dynamics outside the brain. This shows that while the chronic
phase HIV dynamics in the brain may be studied with the brain compartment in
isolation as done in some previous studies [56], the modeling study for acute phase
HIV-1 dynamics should include both the brain and the plasma as one coupled system.
This underscores the importance of getting deeper insights into the BBB and viral
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transport across it.
In addition to the virus entering into the brain from outside, our model com-
parison on the basis of AIC values reveals that there may be ongoing viral replica-
tions and production of new virus inside the brain. However, the infection rate of
macrophages, the major target cells for viral replication inside the brain, is signifi-
cantly smaller than that of CD4+ T cells. This implies that macrophages are less
susceptible than CD4+ T cells to HIV-1, but once infected, they remain so for a much
longer time as indicated by our estimate of a significantly lower death rate of infected
macrophages than infected CD4+ T cells. As a result of these infections outside and
inside the brain, our model predicts that in the long run the virus in the brain reaches
a steady-state nearly three-fold lower than the virus in the plasma. Similarly, there
can be a persistence of infected macrophages in the brain with a steady state level
significantly lower than the infected cells in the plasma. This indicates that without
treatment the virus maintains infectiousness throughout an individual’s lifetime not
only in the plasma, but also in the brain. This long-term persistence of the virus inside
the brain is likely linked to HAND including early-onset dementia and encephalitis
[31, 41, 46, 48, 50].
Importantly, our estimates show that the rate of viral exit from the brain, ψ , is
significantly higher than the rate of viral entry into the brain, ϕ . This rate combined
with persistent low level ongoing viral replication inside the brain indicates that the
brain can be an important reservoir supplying virus into the bloodstream. Since many
antiretroviral drug molecules can not enter the brain through the BBB [46], viral
replication can continue in the brain despite suppression of virus to undetected levels
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in the plasma, thereby causing an obstacle to the cure of HIV through treatment.
Upon treatment interruption, the virus produced in the brain may contribute to
the further replication outside the brain resulting in the viral rebounds. Therefore,
antiretroviral agents that can obstruct the replication inside the brain are necessary
for successful control of virus infection.
We also computed the basic reproduction number, R0 , for each monkey, and
found that the value of R0 (1.33 to 1.55) is consistent with the previous estimates
[74]. Furthermore, we performed a sensitivity analysis to identify the parameters
most affecting R0 . Our results show that those parameters related closely to T cells
are the most impactful for determining the value of R0 , and thus best characterize
the initial infection. This suggests that the brain has minimal effect on the initial
infectiousness of HIV-1. This result is consistent with the facts that the infection
initiates outside the brain first, and it takes some time for the virus to penetrate the
BBB and enter the brain [31].
To understand the effects of the blood-brain barrier on the treatment of HIV-1,
we extended the basic model (from chapter 3) to the model with treatment terms. In
the extended model, we considered two pharmacodynamic terms, namely, the slope
of the dose-response curve, and a CPE score. One important finding from the model
simulations is that the CPE score plays a significant role on the viral suppression
in the brain for drugs with higher slopes (m > 1.9), compared to drugs with low
slopes (m < 1.89). Generally, ART drugs with larger slopes (m > 1.89) tend to be
protease inhibitors [1] (see Table 4). While our predictions suggest that changing the
CPE score does not affect the time that the plasma viral load becomes undetectable
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for either drug type, the CPE score of ART can significantly impact the average
time for the BVL to reach undetectable levels. In particular, for PIs, a higher CPE
score corresponds to a shorter time for the virus to become undetectable in the brain.
However, our simulations did not support a relationship between the CPE score and
the time to viral undetectability in the brain if ART had a drug with a low slope. A
similar phenomena was observed when we included ART with two drugs. Specifically,
for two ART drugs with high slopes, the CPE score per drug affected the days to viral
undetectability in the CSF, however, if ART included a drug with a low slope and a
drug with a high slope, only the CPE score for the drug with a higher slope reduced the
days before the BVL became undetectable. In general, for a PI, a higher CPE score
implies a higher percentage of a drug that reaches the brain, and thus a lower time to
viral undetectability. Hence, our simulations support the results from Letendre [46]
for PIs, which illustrates the impact of the BBB on the potential treatment of HIV
in the brain.
We further considered the effect the BBB has on drug regimens with higher
dose-response curve slopes compared to those with lower slopes. In this case we
found that the PVL reached undetectable levels in significantly less time (≈ 50 days
vs. ≈ 1 day) if the slope of the dose-response curve of a drug measured over 1.9,
independent of the CPE score. This drastic difference in viral reduction time for
PIs was not, observed in the BVL. However, for ART with lower slopes the BVL
becomes undetectable roughly three weeks before the PVL does, unlike the results
from ART with higher slopes. Furthermore, our simulations suggest that the BBB
reduces the effect of ART on HIV in the CSF, especially for drugs with higher slopes.
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Therefore depending on the slope of the dose-response curves, control of the PVL
may not necessarily indicate control of the BVL. For ART protocols with more than
two drugs, viral suppression in the plasma also does not imply viral suppression in
the brain. However, the median days to viral undetectability in the CSF is less if the
number of drugs in an ART protocol is higher. Furthermore, for ART regimens with
higher drug totals, a measure of the plasma viral load may not accurately reflect the
total viral load in the body as viral RNA may still be present in the brain.
The total time viral RNA takes to reach undetectable levels can be quite
different depending on the time of treatment initiation. Although early treatment
may prevent the establishment of a viral reservoir [8], our model simulations suggest
that treatment initiated after 3 dpi, early ART may not always be better. We found
that treatment initiated during the second week post-infection (10-14 dpi) may take
up to 50% more days on average to reduce viral loads to undetectable levels than ART
begun at roughly 9 weeks (60 dpi) post-infection (see Figure 23). Thus, the impact
of the BBB may be limited if treatment begins near the ninth week post-infection.
Furthermore, initiating treatment during the first few weeks of infection may result
in longer periods of high viral loads.
We again computed the viral reproduction number, R0 in the present of ART,
and observed a dependence of R0 on ART effectiveness. It is worth noting that any
combination of ART drugs that satisfies εi+1.78(εPIi)
2 ≥ 0.14εPIi+0.52 will prevent
infection according to this model.
To explore the stochastic effect on the viral dynamics of HIV1 in the brain we
developed a stochastic model and examined the uncertainty that randomness causes
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on the viral dynamics of HIV-1 in the brain as well as the plasma. We note that
our stochastic model captured the average behavior predicted by the deterministic
model. Furthermore, by measuring propensity functions we observed a longer near-
peak infection reaction for both viral infection and viral production in the brain
compared to those in the plasma, suggesting a longer persistence of viral replication
within the brain. This is consistent with findings from several studies [12, 18]. Based
on the reaction propensity values we also note that the reaction with the highest
likelihood varied between plasma viral production and plasma viral clearance. While
results from the deterministic model show a simple decline in virions in the plasma
from the peak (∼ 14 dpi) until day 60, our stochastic model suggests that there are a
few days in week seven in which infection becomes more likely. While the early viral
production reaction suggests early treatment, which supports findings from several
studies [8, 17, 75], treatment during the seventh and eighth week may prove beneficial
to prevent any re-establishment of peak infection, which supports findings from the
model studied in chapter 4.
In order to better understand the stochastic effect of infection, we examined
the probability distributions for each infected cells and free virions during peak in-
fection likelihood. The main observation from these distributions was that there are
significantly more reactions occurring amid early stages of infection compared with
later stages based on distribution variances, which confirms findings from Allen et al.
[80]. However, outside of peak infection time the stochastic effect is lessened signif-
icantly. Furthermore, based off these distribution variances, we observed that viral
infection in the plasma is more controlled by CD4+ T cells, and infected macrophages
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affect the dynamics in the brain. Thus treatment protocols targeting macrophages
may have a greater effect on controlling HIV infection in the brain.
We acknowledge several limitations of this study. We considered only macrophages
as targets of HIV-1 inside the brain. However, brain macrophages may differentiate
into microglia. Also, small amount of CD4+ T cells may exists within the brain [68]
and other cells such as astrocytes may be HIV-1 targets. We did not consider the im-
mune responses, which might be particularly important for the long-term dynamics.
We only studied constant treatment, which in turn, often led to viral eradication. In
fact, constant treatment is unrealistic. The recent study by Vaidya et al. [75] suggests
that the pharmacodynamics of each drug play a large role in latent infection. That
study also found that the basic reproduction number may not be the most reasonable
indicator of infection persistence, suggesting the new threshold called the infection
invasion threshold. We did not take into account drug resistance, nor the potential
for viral mutation, which could result in viral rebound even amid treatment. Some
studies [59, 68] have found that astrocytes and T cells may also transit viral RNA
into the brain, but we only considered macrophages in the brain. While these theo-
retical results offer insight to potential ART treatment improvements, they must be
tested by in vitro and in vivo experiments before any recommendations can be of-
fered in practice. Recent advances have been made in eliminating HIV DNA through
CRISPR technology [21], however we considered only viral RNA. Our model does not
incorporate mutated virus strands which have been known to evade treatment [77].
Future goals stemming from this dissertation include the need to develop and
analyze a model that incorporates a time-varying treatment concentrations to study
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the HIV-infection dynamics in the brain as drug concentrations decay. Also, addi-
tional work is needed to conduct model analysis and the long-term effects of uncer-
tainty (i.e., global analysis for the stochastic model) discussed in chapter 5. Other
areas which could be of interest include: development of a model that can help in
understanding the effects of drugs of abuse on HIV-infection dynamics in the brain,
analysis of multiple virus types–specifically drug-resistant strands of HIV. Further-
more, we could conduct a study that incorporates both the stochastic uncertainty
and time-dependent treatment to extend knowledge on the dynamics of HIV in the
brain.
In summary, we developed models to examine the role of the brain and the BBB
on the viral dynamics of HIV. Our model predictions suggest that the brain may act
as a reservoir of HIV. Furthermore, certain ART drug pharmacodynamic properties
may affect the time for the virus to become undetectable. Since infection reactions
in the brain maintain their peak likelihoods for longer than infection reactions in the
plasma, HIV control strategies that target macrophages that enter the brain may
control HIV are recommended.
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